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ABSTRACT 
There are over 30 missense mutations found in the human insulin gene responsible for 
a newly-characterized diabetic syndrome called Mutant INS-gene-induced Diabetes of 
Youth (MIDY). In MIDY, mutations in the insulin gene lead to toxic misfolding of mutant 
proinsulin in the endoplasmic reticulum (ER). Importantly, MIDY proinsulin mutants bind 
to and sequester wild-type (WT) proinsulin via mixed disulfide bonds in the ER, resulting 
in decreased insulin maturation and secretion. These mixed disulfide-bonded WT-
mutant complexes oligomerize into high molecular weight (HMW) species, eventually 
forming toxic insoluble aggregates that lead to β-cell death. To alleviate the disease, we 
posit that the efficient degradation of the MIDY mutant proinsulins should allow WT 
proinsulin to properly fold in the ER and mature into insulin poised for secretion. 
 
In this thesis, we uncover two ER-dependent protein quality control pathways that are 
used to eliminate the classic MIDY mutant proinsulin Akita. We first reveal that Akita is 
degraded via the ER-associated degradation (ERAD) pathway. In this pathway, the ER-
resident chaperone Grp170 acts to prevent aggregation of the Akita HMW complex, 
while the PDI redox enzyme reduces the HMW species to generate ERAD-competent 
smaller oligomers of Akita. These smaller Akita oligomers in turn translocate across the 
ER membrane via the Hrd1-Sel1L membrane proteins and are extracted into the cytosol 
by the p97 ATPase. Upon reaching the cytosol, Akita is delivered to the proteasome for 
destruction. Strikingly, we found that enhancing Grp170-dependent ERAD degradation 
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of Akita led to restoration of WT insulin secretion. In a second and distinct protein 
quality control pathway, we discovered that the Akita aggregates (that are formed 
despite the action of Grp170) are in fact removed by a RTN3-dependent ER-coupled 
autophagy (ER-phagy) pathway. Importantly, RTN3-dependent clearance of 
aggregated Akita also stimulates WT insulin secretion.  
 
In sum, my thesis unveils a two-pronged quality control strategy – ERAD and ER-phagy 
– that are strategically deployed against a mutant proinsulin molecule. Our results raise 
the possibility that enhancing the activities of key components within the ERAD and ER-
phagy pathways that stimulate degradation of mutant proinsulins and concomitantly 
promote WT insulin secretion may provide a rational therapeutic approach to combat 
MIDY. 
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CHAPTER 1: Introduction 
Approximately one-third of the human proteome enters the endoplasmic reticulum (ER) 
to fold and traffic to their proper spatial positions along the secretory pathway or to be 
secreted out of the cell (Braakman and Hebert, 2013). The extracellular environment is 
more oxidizing than the cytosolic milieu, so eukaryotic cells need internal compartments 
to prepare proteins for a life outside of the cell. The rich oxidative environment of the ER 
makes it ideal for polypeptide biosynthesis and folding. During protein biosynthesis, 
ribosome-nascent chains destined to the ER recruit the signal recognition particle (SRP) 
to the signal sequence on the nascent chain (Chartron et al., 2016; Connolly and 
Gilmore, 1989). This binding slows translation until the ribosome is selectively docked at 
the SRP receptor of the ER, where release of the SRP recommences polypeptide 
synthesis into the ER in a process known as cotranslational translocation (Rapoport, 
2007). Distinct from cotranslational translocation, a subset of nascent polypeptide 
chains are targeted to the ER via a process known as posttranslational translocation. In 
this case, fully synthesized proteins do not require SRP. Instead, cytosolic chaperones 
guide the new polypeptides to the ER membrane translocation complex where the 
chaperones release the polypeptide chains, enabling their translocation through the 
Sec61 translocon (Plath and Rapoport, 2000). Soluble proteins cross the Sec61 
translocon via a ratcheting mechanism in which iterative cycles of binding to Binding 
Immunoglobulin Protein (BiP) drive forward translocation (Matlack et al., 1999). 
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Removal of the signal sequence by signal peptidase untethers the polypeptide from the 
ER membrane, thereby releasing the polypeptide within the ER lumen (Figure 1-1).  
 
In the ER lumen, the polypeptide engages chaperones of the heat shock protein (HSP) 
families, lectins, and oxidoreductases, such as the protein disulfide isomerase (PDI) 
family; these chaperones assist the polypeptide chain to obtain its tertiary and 
quaternary native structures (Braakman and Hebert, 2013) (Figure 1-1). To support 
folding, the polypeptide chain is often subjected to multiple posttranslational 
modifications, including glycosylation, disulfide bond oxidation, as well as cis-trans 
prolyl isomerization (Ellgaard et al., 2016). Upon proper folding, the polypeptide chain is 
no longer associated with ER resident quality control proteins and is ready to exit the 
ER and be transported to the cis Golgi apparatus via COPII-coated vesicles (Barlowe et 
al., 1994). Eventual transport of the folded polypeptide chain out of the trans Golgi 
network enables it to traffic further to the cell surface or to the endo-lysosomal 
membranous system where it can reside and function.  
 
While many aspects of protein folding in the ER have been elucidated, it remains 
unclear how the cell deploys quality control mechanisms to determine the fate of 
improperly folded polypeptides. The research presented in this thesis focuses on how 
pancreatic β-cells handle a terminally misfolded insulin precursor protein as a model to 
understand these quality control processes, and to further clarify the underlying causes 
of a severe form of diabetes. The following introductory sub-sections highlight our 
3 
 
current understanding of protein quality control mechanisms that exist to maintain 
cellular proteostasis. 
 
Unfolded Protein Response 
Protein misfolding is the etiology of many human diseases including but not limited to 
Parkinson’s Disease (PD), Huntington’s Disease (HD), Alzheimer’s Disease (AD), and 
some forms of cancer and diabetes. In this collection of maladies, mutant or misfolded 
disease-causing proteins accumulate and often aggregate, leading to severe cellular 
stress (Bates, 2003; Irvine et al., 2008). In AD, amyloid β-peptide aggregates outside of 
neurons leading to toxic plaque formation (Tanzi and Bertram, 2005), while a phenotype 
of PD involves α-synuclein molecules aggregating in Lewy Bodies, which are 
cytoplasmic inclusions that hinder proper neuron homeostasis (Spillantini et al., 1997). 
In HD, polyglutamine repeats in the huntingtin protein results in severe aggregation 
(Bates, 2003; Scherzinger et al., 1997). Collectively, these diseases represent models 
of protein-misfolding diseases which are significant human health concerns. 
 
Interestingly, a majority of the aforementioned protein aggregates are cytosolic or 
extracellular in nature. Rarely are protein aggregates found within the ER of specific 
cells (Vincenz-Donnelly et al., 2018). As indicated, the ER has a rich chaperone and 
oxidative environment which laboriously assists polypeptides to achieve their native 
structure. However, even within this environment, proteins can misfold (Wang and 
Kaufman, 2016) (Figure 1-1). Some proteins misfold in the ER due to genetic mutations 
(see below), or because they possess highly hydrophobic, disordered regions or 
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complex tertiary structures. Regardless of the cause, the ER must respond to misfolded 
protein accumulation before these proteins ultimately cause ER stress or aggregate into 
toxic misfolded species (Wang and Kaufman, 2016) (Figure 1-1).  
 
In this context, the ER has developed a homeostatic quality control pathway called the 
unfolded protein response (UPR) which is designed to respond to the accumulation of 
misfolded proteins. Originally coined by Mary-Jane Gething and Joseph Sambrook, 
UPR regulates and minimizes ER stress by controlling the levels of ER chaperone and 
protein at the transcriptional and translational levels (Gething and Sambrook, 1992; 
Kozutsumi et al., 1988). UPR is divided into three major arms: ATF6, PERK, and IRE1.  
 
The ATF6 arm of the UPR is a relatively defined pathway. While the mechanism by 
which ATF6 senses misfolded ER proteins remains elusive, the downstream and 
transcriptional activation of this transmembrane protein is more clearly understood. 
Upon sensing the accumulation of misfolded ER proteins, the ER-resident ATF6 
migrates to the Golgi, where two site-specific proteases cleave ATF6 to generate a 
cytosolic fragment of ATF6 (Haze et al., 1999; Ye et al., 2000). This fragment 
translocates to the nucleus where its acts as a transcriptional activator of genes 
encoding HSPs, PDIs, and additional ER chaperones (Walter and Ron, 2011). Hence, 
this arm of UPR enhances the folding capacity of the ER in order to alleviate 
accumulation and potential aggregation of misfolded proteins. 
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Conversely, the PERK arm of UPR lessens protein folding load, thereby alleviating ER 
stress. After sensing the accumulation of misfolded ER proteins, the PERK 
transmembrane serine/threonine kinase undergoes dimerization and 
autophosphorylation. This initiates a signaling cascade leading to the phosphorylation of 
eIF2α, the latter of which directly downregulates protein influx by inhibiting protein 
translation (Harding et al., 2000).  
 
In the IRE1 arm of the UPR, inactive IRE1 is initially bound by BiP. BiP dissociates from 
IRE1 due to buildup of misfolded ER proteins. Oligomerization and phosphorylation 
activate IRE1’s endonuclease activity, which cleaves mRNAs to translationally repress 
the biosynthesis of new proteins (Korennykh et al., 2009). IRE1 also splices the Xbp1 
mRNA which generates an active Xbp1 transcription factor that upregulates the 
expression of numerous ER chaperones (Yanagitani et al., 2011). 
 
In the context of this thesis, many UPR-upregulated genes are components of a major 
quality control pathway called ER-associated degradation (ERAD) (Travers et al., 2000) 
(Figure 1-1,1-2; see below). This pathway is one of two known mechanisms by which 
the ER removes misfolded ER substrates for degradation. 
 
ERAD and ER-phagy Dependent Protein Quality Control 
 
ERAD is the major ER quality control pathway that disposes misfolded ER luminal and 
ER membrane proteins for 26S proteasome degradation in the cytosol. This is executed 
using a process known as retrotranslocation whereby ERAD components move 
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misfolded proteins to the cytosol (Werner et al., 1996) (Figure 1-2). ERAD is an intricate 
system of concerted chaperones and enzymes that recognizes misfolded clients, 
retrotranslocates them through an ER membrane channel, poly-ubiquinates the 
misfolded clients for their extraction, and delivers them to the proteasome for 
degradation. ERAD is categorized into three groups, depending on the nature of the 
misfolded client: ERAD-L represents a pathway that disposes a soluble or membrane 
protein in which the recognized substrate begins in the lumen, ERAD-M represents a 
pathway that degrades a membrane substrate containing a lesion within the 
transmembrane domain, and ERAD-C represents a pathway that disposes a membrane 
substrate with a lesion in the cytosolic domain (Ruggiano et al., 2014). For the research 
presented in this thesis, ERAD-L will be the focus. 
 
For misfolded ER luminal proteins to undergo ERAD, the client must be first recognized 
by ERAD luminal components. These components include, but are not limited to, 
Hsp70s and their co-chaperones, Hsp90s, Hsp40s, and ER oxidoreductases. One 
example of these chaperones is the ER-resident Hsp70 chaperone BiP. BiP harbors a 
substrate binding domain (SBD) which recognizes short unfolded amino acid 
sequences, and a nucleotide binding domain (NBD). Through ATP hydrolysis stimulated 
by an Hsp40 harboring a J-domain, BiP-ADP interacts with a substrate via its SBD. The 
SBD of BiP is relatively nonspecific (Marcinowski et al., 2011; Pobre et al., 2019; Yang 
et al., 2017) allowing BiP to have a multitude of diverse substrates. Apo-BiP targets a 
substrate to membrane-bound ERAD components before BiP is released from the 
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substrate via the action of one of two ER-resident nucleotide exchange factors (NEF) 
Sil1 or Grp170 (Behnke et al., 2015; Inoue and Tsai, 2015; Weitzmann et al., 2006). 
 
In addition to acting as a NEF of BiP, Grp170 can also function as a chaperone. In fact, 
it has a higher propensity than BiP to bind to and sequester terminally misfolded 
substrates that are destined for ERAD (Behnke and Hendershot, 2014). In concert with 
ERdj4 and ERdj5, Grp170 recognizes misfolded protein sequences that are buried in 
properly folded clients (Behnke et al., 2016) (Figure 1-2). When a client is misfolded, 
these three co-chaperones, along with BiP and other chaperones, delivers it directly to 
ERAD (Figure 1-2).  
 
In addition to the HSPs, ER oxidoreductases are necessary for clients that contain 
disulfide bonds (Figure 1-2). ER oxidoreductases, such as the aforementioned PDI 
family, use conserved Cys-X-X-Cys motifs to reduce, oxidize, or isomerize cysteines 
involved in disulfide bonds (Hatahet and Ruddock, 2009; Tu et al., 2000). This family of 
over 20 ER oxidoreductases are responsible for reducing disulfide bonds for clients to 
be funneled through the retrotranslocon, the ERAD membrane channel (see below). An 
example of client reduction was shown by the ERdj5-mediated reduction of mutant low-
density lipoprotein receptors (LDLR), a required step for LDLR retrotranslocation and 
degradation (Oka et al., 2013). Together with HSPs, these chaperones and enzymes 
coordinately recognize and prepare ERAD clients for dislocation through the ER 
membrane. 
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After misfolded proteins have been recognized as substrates destined for 
retrotranslocation, they are delivered to ER membrane ERAD components, specifically 
an E3 ubiquitin ligase and its adaptors. Hrd1, an E3 ubiquitin ligase and its adaptor 
Sel1L, are members of the canonical ERAD pathway (Figure 1-2). Hrd1 is a multi-pass 
transmembrane E3 ubiquitin ligase featuring a RING finger domain on its cytosolic tail 
(Schoebel et al., 2017). Importantly, Hrd1 was demonstrated to be the retrotranslocon, 
the channel by which misfolded clients are retrotranslocated through the ER membrane 
from the ER lumen into the cytosol (Baldridge and Rapoport, 2016). Its major adaptor 
protein Sel1L is single-pass type I transmembrane protein with a large N-terminal 
luminal domain containing nine Sel1-like repeats (SLRs), tetratricopeptide repeats 
which mediate protein-protein interactions (Mueller et al., 2006; Ye et al., 2004). 
Delivery of reduced clients to Sel1L via luminal chaperones mediates client transition to 
the Hrd1 retrotranslocon. Once lysine residues are exposed on the cytosolic surface of 
the retrotranslocon, Hrd1’s RING domain poly-ubiquitinates the clients prior to their 
extraction into the cytosol (Stein et al., 2014) (Figure 1-2).  
 
Cytosolic extraction of the polyubiquitinated client requires an AAA+ ATPase called 
p97/VCP and its co-factors Npl4 and Ufd1 (Bodnar et al., 2018; Ye et al., 2001) (Figure 
1-2). In order to extract polyubiquitinated clients to the cytosol, p97 uses ATP hydrolysis 
at each of its Walker A and Walker B domains to generate sufficient force to eject the 
client into the cytosol (Meyer et al., 2012). Interestingly, misfolded clients cannot be 
extracted from the ER (or proteoliposomes) in the absence of Npl4 and Ufd1, 
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demonstrating a critical need for these components for proper extraction and delivery to 
the proteasome. 
 
If misfolded proteins are incompetent to undergo ERAD because they form large 
aggregates, the ER can deploy another major degradative pathway called ER-coupled 
autophagy (or ER-phagy). Autophagy is a catabolic process in which the cell recycles 
damaged organelles or portions of organelles for homeostatic maintenance. In the case 
of a damaged organelle, autophagic initiation factors (i.e. Atg proteins, Beclin1, 
LC3/GABARAP) create a phagophore, which is an isolated membrane that begins to 
encapsulate the organelle (Parzych and Klionsky, 2014). The phagophore matures 
through an intricate expansion process to surround the target organelle and seals to 
become an autophagosome. This autophagosome fuses with the lysosome to allow for 
lysosomal breakdown and degradation of the internal organelle and its constituents.  
 
One of the earliest pieces of evidence of ER-phagy was the observation of ER-derived 
cisternae within autophagosomes after ER stress-induction (Bernales et al., 2006). Prior 
to this finding, a model ER-resident HDEL substrate was discovered in the vacuole 
under starvation conditions, suggesting that segments of the ER are degraded via 
autophagy (Hamasaki et al., 2005). Together, these results introduced two new exciting 
concepts: the existence of an ER-specific autophagy pathway (Figure 1-3), and a strong 
relationship between the UPR and autophagy.   
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A key question in ER-phagy is how accumulation of large aggregates in the ER “signals” 
to the cytosolic macroautophagy machinery to fragment specific ER segments. One 
hypothesis is that ER transmembrane receptors, acting as ER-phagy receptors, must 
transmit this signal (Figure 1-3). These receptors would directly link the buildup of large 
aggregates in the ER to the core cytosolic macroautophagic machinery. To date, four 
ER-phagy receptors have been identified, namely FAM134B, Sec62, Cell Cycle 
Progression Gene 1 (CCPG1), and Reticulon3 (RTN3) (Figure 1-3). Each of these 
receptors contain at least one LC3-interacting region (LIR), a crucial motif that enables 
the receptors to connect to the core macroautophagic machinery (Birgisdottir et al., 
2013) (Figure 1-3). 
 
Perhaps the most-well studied of these receptors is FAM134B (homologous to Atg40 in 
yeast). FAM134B is an integral membrane protein, containing a N-terminal cytosolic tail, 
a reticulon-homology domain (RHD), and a C-terminal cytosolic tail containing one LIR 
(Figure 1-3). Localized to ER sheets, FAM134B was the first mammalian ER-phagy 
receptor to be identified that assist in the turnover of ER segments to the lysosome for 
degradation (Khaminets et al., 2015; Mochida et al., 2015). Moreover, recent studies 
have identified specific cargos for FAM134B-dependent ER-phagy (Forrester et al., 
2019; Schultz et al., 2018). 
 
Relevant to this thesis is the ER-phagy receptor RTN3. Reticulons are wedge-like 
sculptors of the ER, creating a complex and dynamic network of tubular ER branches 
emanating from ER sheets. Each reticulon harbors an RHD region with varying lengths 
of N- and C-terminal cytoplasmic tails. Moreover, reticulons gene products are subject 
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to differential splicing, generating smaller isomers (Yang and Strittmatter, 2007). For 
example, RTN4 has 3 splice variants, with RTN4A being full length and 4B and 4C 
having shorter N-terminal tails (Yang and Strittmatter, 2007). The expression of RTN4A 
is almost exclusively neural while RTN4B is found in most tissues (Oertle and Schwab, 
2003; Ramo et al., 2016). While reticulons have been studied for years, only recently 
was RTN3’s role in ER-phagy discovered.  
 
Analogous to FAM134B, RTN3 is an integral membrane protein, extending only as far 
as the cytosolic-facing leaflet of ER membrane. This receptor contains six LIR domains 
on its N-terminal cytosolic tail. Although RTN3-mediated ER-phagy has been shown to 
promote ER tubule turnover during starvation conditions (Grumati et al., 2017), no 
known cargos of RTN3-mediated ER-phagy have yet been reported.  
 
Because many diseases result from protein misfolding, cells must deploy ER protein 
selective degradative mechanisms, including ERAD and ER-phagy, in order to maintain 
proper homeostasis. A key gap in our knowledge is how specific misfolded substrates 
are recognized by these pathways and efficiently degraded. The research presented in 
Chapters 2-4 focuses on how the ERAD and ER-phagy protein quality control pathways 
are deployed in response to misfolding of a mutant proinsulin molecule that causes a 
newly identified form of diabetes called Mutant INS-gene-induced Diabetes of Youth 
(MIDY).   
 
Mutant INS-gene-induced Diabetes of Youth (MIDY) 
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Insulin is a peptide hormone secreted from pancreatic β-cells to regulate blood glucose 
levels. Similar to other peptide hormones, insulin is synthesized as an inactive 
precursor. Preproinsulin harbors a N-terminal signal sequence, followed by a B chain, a 
connecting C-peptide, and an A chain. Preproinsulin is co-translationally translocated 
into the ER where signal peptidase cleaves the signal sequence resulting in formation of 
proinsulin (Chan et al., 1976; Steiner et al., 1967). Proinsulin then undergoes multiple 
rounds of oxidative folding in which three conserved disulfide bonds are formed.  
 
The first disulfide bond formed is between the cysteine at the 19th residue on the B 
chain (named B19) and the cysteine at the 20th position on the A chain (A20), thereby 
generating the B19-A20 disulfide bond (Haataja et al., 2016; Hua et al., 2006; Yan et al., 
2003). Once this is generated, two additional disulfide bonds will form between cysteine 
B7 and cysteine A7 (called the B7-A7 disulfide bond) and a final intrachain A6-A11 
disulfide bond. Upon proper folding, non-covalent proinsulin dimers exit the ER via 
COPII-coated vesicles, followed by transport through the Golgi apparatus where 
proinsulin is packaged into immature secretory granules. Here prohormone convertase 
PC1/3 and PC2 excise proinsulin’s C-peptide. The resulting bioactive insulin, with its B 
and A chains connected via the B7-A7 and B19-A20 disulfide bonds, is poised for 
secretion. 
 
Mutant INS-gene-induced Diabetes of Youth (MIDY) is an autosomal dominant diabetes 
mellitus (DM) characterized by early age of onset, severe hyperglycemia, and β-cell 
death (Liu et al., 2010a; Stoy et al., 2007; Weiss, 2009, 2013). As the name suggests, 
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MIDY is caused by mutations in the INS gene. Over the past decade, ~30 MIDY 
mutations have been identified. These missense mutations do not map to a specific 
region of the proinsulin molecule. Instead, they tend to be found in conserved 
hydrophobic residues or at the cysteines themselves (Liu et al., 2010b). 
 
MIDY mutations result in proinsulin misfolding in the ER (Figure 1-4). When this occurs, 
proinsulin fails to exit the ER. As a result, its maturation through the secretory pathway 
does not occur and the β-cell fails to make sufficient insulin. Despite this, the failed 
maturation of these mutant proinsulins is not the direct cause of insulin deficiency. 
Instead, mutant proinsulin binds to and interferes with ER exit of WT proinsulin. A 
majority of MIDY mutant proinsulins form mixed disulfide-linked complexes with 
coexpressed WT proinsulin in the ER leading to decreased WT insulin secretion (Liu et 
al., 2010a). Surprisingly, this toxic gain of function effect on bystander WT occurs even 
in MIDY mutants where the missense mutation does not feature a cysteine addition or 
subtraction. For instance, the L(B11)P and G(B23)V mutants decrease total mature 
insulin while also engaging WT in disulfide-linked complexes (Liu et al., 2010a). In the 
case of the G(B23)V MIDY mutant, its inability to interchain disulfide bond between the 
B and A chains ultimately leads to availability of the free thiols to engage in mixed 
disulfide bonds with coexpressed WT proinsulin (Liu et al., 2010a; 2010b). Thus, while 
not directly adding or subtracting out a cysteine residue, some MIDY proinsulin mutants 
are unable to properly fold resulting in free reactive thiols that readily engage 
coexpressed folding WT proinsulin (Figure 1-4). 
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Based on this insight, MIDY can conceptually be managed by two approaches. The first 
is to promote efficient WT proinsulin folding such that it can “escape” from the MIDY 
proinsulin mutant by rapidly exiting the ER. The second is to selectively degrade the 
MIDY proinsulin mutant. In this scenario, efficient removal of MIDY proinsulin mutant 
from the ER would allow bystander WT proinsulin to fold properly and exit the ER, 
producing mature bioactive insulin that would alleviate the disease phenotype. My 
thesis is motivated by the second conceptual approach. 
 
Prior to my work, the underlying ER quality control mechanisms that degrade MIDY 
proinsulin mutants were not fully understood. Although previous studies implicated UPR 
and several components of ERAD and autophagy as involved in removing mutant 
proinsulin (Allen et al., 2004; Bachar-Wikstrom et al., 2013; Gupta et al., 2010), 
mechanistic insights into how mutant proinsulins were triaged and degraded were 
lacking. In this thesis, I have focused on one model mutant proinsulin called Akita, a 
mutation in which the cysteine at the 7th position on the A chain is mutated to a tyrosine 
(Wang et al., 1999). The Akita proinsulin mutant fails to make the B7-A7 disulfide bond 
essential for proper folding in the ER. This results in the Akita mutant proinsulin forming 
massive disulfide-linked protein complexes with other Akita and WT proinsulin 
molecules, causing severe ER stress (Figure 1.4). Human patients and rodent models 
of Akita-mediated MIDY develop DM neonatally (human at <6 months of age; mice at 4 
weeks of age). Akita males have extreme hyperglycemia, β-cell apoptosis, and often die 
around 12-14 weeks after birth  (Izumi et al., 2003; Liu et al., 2007; Wang et al., 1999). 
For these reasons, Akita is an attractive misfolded model substrate for the MIDY 
15 
 
disease. The study of Akita should enable us to clarify the ER quality control 
mechanisms used to maintain cellular homeostasis in an effort to avoid or alleviate 
disease progression. 
 
This thesis aims to address several major unknown questions: how is Akita mutant 
proinsulin degraded? What components of ER quality control triage and degrade the 
misfolded mutant proinsulin? Can modulating ER quality control mechanisms enhance 
Akita degradation to ultimately rescue WT insulin secretion deficiencies in the disease? 
Chapter 2 of this thesis uncovers how Akita mutant proinsulin is recognized by an ER 
oxidoreductase called protein disulfide isomerase (PDI). My analyses revealed that PDI 
acts as a reductase, reducing Akita high molecular weight disulfide-bonded complexes 
to smaller oligomeric species that are competent to undergo ERAD. In this pathway, 
Akita retrotranslocates across the Hrd1 E3 ubiquitin ligase and is extracted into the 
cytosol by the p97 ATPase en route to the proteasome for degradation. In Chapter 3, I 
begin to dissect the role of the ER luminal chaperone Grp170 in triaging Akita. I found 
that overexpression of Grp170 enhances Akita degradation, thereby restoring WT 
insulin secretion – this finding provided a proof-in-principle strategy to alleviate the 
MIDY disease. In Chapter 4, I further clarify Grp170’s molecular function by revealing 
that it acts to prevent aggregation of Akita. Strikingly, my results demonstrate that if 
Akita continues to aggregate despite the presence of Grp170, the ER-phagy receptor 
RTN3 can help to dispose of these aggregates via the ER-phagy pathway. This, to our 
knowledge, is the identification of the first substrate for RTN3-dependent ER-phagy.  
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In summary, the collective findings presented in my thesis elucidate how a specific 
misfolded ER substrate - Akita mutant proinsulin - is recognized, triaged, and degraded 
by coordinated ER quality control mechanisms. I envision that insights from this work 
can provide a framework for a rational approach to alleviate the MIDY disease. 
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Figure 1-1. Protein folding and misfolding in the Endoplasmic Reticulum. Newly 
synthesized polypeptides enter the endoplasmic reticulum (ER) by translocation through 
the Sec61 channel via a ratcheting mechanism performed by the Hsp70 chaperone BiP. 
In the ER, multiple rounds of oxidative folding will assist the polypeptide fold into its 
native, functional structure. If problems arise, other chaperones (i.e. PDI 
oxidoreductases, Hsp40s, Hsp70s, Hsp90s) will attempt to refold the misfolded 
substrate. When correctly refolded, the polypeptide can exit the ER for anterograde 
transport through the endomembrane system. Proteins that fail to reach a correct 
conformational state can be degraded via the ERAD pathway (cytosolic proteasomal 
degradation) or ER-phagy (lysosomal degradation) if aggregation occurs. Misfolded 
protein accumulation will activate the Unfolded Protein Response (UPR), which directly 
upregulates ERAD and ER-phagy components to assist in removal of these misfolded 
substrates. 
18 
 
 
 
Figure 1-2. Canonical Endoplasmic Reticulum-associated degradation (ERAD-L) 
pathway. Misfolded ER-luminal clients will be selectively recognized and triaged by ER-
resident chaperones. Substrates that contain disulfide bonds will be reduced by ER 
oxidoreductases, preparing the substrate for delivery to the ERAD ER-membrane 
channel. Here, the substrate will be passed to Sel1L, the major adaptor for Hrd1, the E3 
ubiquitin ligase and retrotranslocon. Once chaperones dissociate from the substrate, the 
substrate will be dislocated through the Hrd1 channel. Once exposed on the cytosolic 
surface of the ER, Hrd1 polyubiquitinates the substrate through its RING domain. 
Extraction from Hrd1 involves the AAA+ ATPase, p97, and its co-factors Npl4 and Ufd1. 
p97 will then deliver the polyubiquitinated substrate to the 26S proteasome for 
degradation. 
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Figure 1-3. ER-phagy pathway and structural analysis of the ER-phagy ER-
receptors. ER luminal and membrane misfolded clients unable to undergo ERAD can 
be degraded by ER-phagy. ER-phagy begins with signaling from one of four ER-phagy 
ER-receptors: ER sheet localized FAM134B, Sec62, and CCPG1, and ER tubule 
localized RTN3. These receptors directly link to LC3-II, the lipidated LC3, initiating 
phagophore recruitment and engulfment of a segment of ER membrane and lumen. The 
phagophore expands and closes off forming an autophagosome which then fuses 
downstream with the lysosome. Internal proteins and lipids will be degraded in the 
lysosome for nutrient recycling and to restore homeostasis. 
 
 
 
 
 
 
 
20 
 
 
Figure 1-4. Pathogenesis of the Akita proinsulin mutant in Mutant INS-gene-
induced Diabetes of Youth. Akita (A in purple) mutant proinsulin binds to WT 
proinsulin (WT in green) via mixed disulfides, sequestering it within the ER. As a result, 
WT proinsulin cannot mature and secrete as insulin. Misregulation of blood glucose 
levels signals back to pancreatic b-cells to upregulate the insulin gene. However, this 
exacerbates the problem as more Akita and WT proinsulin enter the ER, oligomerize 
into high molecular weight complexes which induce severe ER stress and β-cell demise. 
To counteract this toxic gain of function effect from Akita proinsulin, pancreatic β-cells 
may use ERAD, ER-phagy, or other ER protein quality control mechanisms to degrade 
the misfolded Akita.  
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CHAPTER 2: PDI Reductase Acts on Akita Mutant Proinsulin to Initiate 
Retrotranslocation Along the Hrd1/Sel1L-p97 Axis 
 
He K, Cunningham CN, Manickam N, Liu M, Arvan P, Tsai B. PDI reductase acts 
on Akita mutant proinsulin to initiate retrotranslocation along the Hrd1/Sel1L-p97 
axis. Mol Biol Cell. 2015;26(19):3413-23. 
 
INTRODUCTION 
Insulin biosynthesis is initiated when preproinsulin is translocated into the endoplasmic 
reticulum (ER) (Steiner et al., 1967) and its signal sequence is cleaved to generate 
proinsulin. Oxidative folding of proinsulin ensues (Liu et al., 2012), characterized by 
formation of three highly conserved disulfide bonds (denoted as B7-A7, B19-A20, and 
A6-A11). Properly folded proinsulin then exits the ER, is transported to the Golgi, and is 
delivered to secretory granules, where pro–hormone convertases excise the C-peptide, 
with B and A chains of mature insulin remaining attached via B7-A7 and B19-A20 
interchain disulfide bonds. 
 
Recently a subset of human insulin gene mutations has been discovered to cause an 
autosomal-dominant syndrome that we call mutant INS gene–induced diabetes of youth 
(MIDY; (Liu et al., 2010a; Stoy et al., 2007; Weiss, 2013)): insulin-deficient diabetes 
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without islet autoantibodies. MIDY is a protein-misfolding disease, and most MIDY 
proinsulin mutants misfold within the ER, causing permanent neonatal or later-onset 
diabetes, depending upon the particular mutation. Among these, the most-studied MIDY 
mutant is Akita proinsulin: substitution at the A7 cysteine causes severe early-onset 
diabetes in both humans and Akita mice. 
 
MIDY mutants fail to be transported from the ER to the Golgi complex. Moreover, MIDY 
mutants impair wild-type (WT) proinsulin exit from the ER, thereby limiting WT insulin 
production, provoking increased blood glucose excursions, and stimulating expression 
of even more proinsulin (both mutant and WT), which remains entrapped within the ER 
(Liu et al., 2007; Weiss, 2013). This triggers ER stress that may ultimately result in β-
cell death. 
 
Eliminating buildup of mutant proinsulin in the ER might restore β-cell function and 
survival. This possibility motivates us to investigate cellular mechanisms of degradation 
of misfolded proinsulin. One such mechanism is the ER-associated degradation (ERAD) 
pathway (Smith et al., 2011; Tsai et al., 2002). In ERAD, a misfolded ER substrate must 
first be identified by ER lumenal components and then delivered across 
(retrotranslocated) to the cytosolic side of the ER membrane for ubiquitination, with the 
assistance of ERAD membrane components (Carvalho et al., 2010; Stein et al., 2014). 
Finally, the ubiquitinated substrate is extracted from the ER membrane into the cytosol 
for delivery to proteasomes for degradation (Ye et al., 2001). 
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There is reason to suspect that MIDY mutants may use the ERAD pathway (Allen et al., 
2004; Hartley et al., 2010; Tiwari et al., 2013), although how misfolded proinsulin in the 
ER lumen is recognized and primed for retrotranslocation remains unknown. Here we 
establish that canonical ERAD membrane components, including the E3 ubiquitin ligase 
Hrd1, its membrane-binding partner Sel1L, and cytosolic p97, help to conduct Akita 
proinsulin from the ER lumen to the cytosol. Strikingly, we find that protein disulfide 
isomerase (PDI), a profolding enzyme known to drive oxidation of disulfide bonds 
(Benham, 2012; Hatahet and Ruddock, 2009), instead exhibits a novel interaction with 
misfolded proinsulin to exert a prodegradative role that includes reducing proinsulin 
disulfide bonds. Our findings provide a framework for rational therapeutic approaches to 
preventing and treating diabetes provoked by proinsulin misfolding. 
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MATERIALS AND METHODS 
Reagents 
Antibodies used were as follows: rabbit anti-Myc (Immunology Consultants 
Laboratories, Portland, OR); mouse anti-VCP (p97), anti-PDI (RL90), and anti-ERp57 
(Abcam, Cambridge, MA); rabbit anti-Hrd1 (Proteintech, Chicago, IL); rabbit anti-Hsp90 
(H-114; Santa Cruz Biotechnology, Santa Cruz, CA); mouse anti-ubiquitin (Invitrogen, 
Carlsbad, CA); rabbit anti-FLAG, anti-Sel1L, and mouse and rabbit horseradish 
peroxidase (HRP) secondary antibodies (Sigma-Aldrich, St. Louis, MO); rabbit anti-Myc 
(9E10) for immunoprecipitation (IP; K. Verhey, University of Michigan, Ann Arbor, MI). 
Chemicals were from Sigma-Aldrich except when noted otherwise. 
Phenylmethylsulfonyl fluoride (PMSF) was from Acros Organics; DMEM, RPM1 1640 
medium, and other cell culture reagents were from Life Technologies (Carlsbad, CA). 
An expression plasmid encoding Myc-epitope–tagged human C(A7)Y Akita mutant 
proinsulin (Akita-Myc) was previously described (Liu et al., 2010b). A second expression 
plasmid encoding Myc-tagged human C(A7)Y proinsulin was constructed in which all 
five remaining Cys residues were mutated to Ser residues; this kind of construct, 
previously referred to as proinsulin-DelCys (Liu et al., 2010a), is also known here as 
ΔCys-Myc. Six related expression plasmids encoding Myc-tagged human proinsulin 
were constructed in which five Cys residues were mutated to Ser; each construct 
retains only one Cys residue, and they are referred to as Keep B7, Keep B19, Keep A6, 
Keep A7, Keep A11, and Keep A20, respectively. Purification of His-tagged PDI from 
bacteria was as previously described (Forster et al., 2009). Human PDI trap mutants 
were gifts from T. Rapoport (Harvard University, Cambridge, MA). The INS-1 832/13 β-
31 
 
cell line was a generous gift from Christopher Newgard (University of Texas 
Southwestern, Dallas, TX). 
 
Cell culture, plasmid transfection, cycloheximide chase, immunoprecipitation, 
and immunoblotting 
Rat INS-1 832/13 or human HEK 293T cells were cultured at 37°C in a humid incubator 
(5% CO2). Cells were seeded on six-well plates 1 d before transfection of 1–3 μg of 
plasmid DNA using home-made polyethylenimine (PEI) or Lipofectamine 2000 
(Invitrogen). At 4 h posttransfection, cells were treated with cycloheximide (100 μg/ml) 
and chased for 0, 2, 4, and 6 h. In experiments using ΔCys-Myc or single-Cys Keep 
mutants, cells were treated with MG132 (10 μM) for 3 h before cell lysis. Cells were 
harvested in phosphate-buffered saline (PBS) containing 10 mM N-ethylmaleimide 
(NEM). For IP, cells were lysed in 400 μl of RIPA buffer (Tris-HCl, pH 7.5, 150 mM 
NaCl, 1% NP-40, 1% sodium dexoycholate, 0.1% SDS) supplemented with 10 mM NEM 
and 1 mM PMSF; in Figure 3H, the modified RIPA buffer contained 0.25% SDS. Cells 
were incubated on ice for 10 min and centrifuged, and the resulting whole-cell extract 
(WCE) was incubated with antibody (1:200) at 4°C for 24 h, followed by 2 h of 
incubation with precleared protein A/G-agarose beads at 4°C. Beads were washed 
three times and boiled in SDS sample buffer with or without 100 mM DTT. For 
immunoblot analyses, cells were lysed in 100 μl of RIPA buffer to generate WCE, which 
was boiled in SDS sample buffer with 100 mM DTT. Then samples were resolved on 8–
15% SDS–PAGE gels, transferred to nitrocellulose, and blotted with specific primary 
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and HRP-conjugated secondary (1:2000) antibodies according to manufacturer’s 
protocols (Sigma-Aldrich). 
 
siRNA knockdown of Hrd1, Sel1L, and PDI 
siRNA was transfected into cells using RNAiMAX (Invitrogen), and cells were chased 
and harvested 48–72 h posttreatment. The sequences of the siRNAs are as follows: 
Dharmacon human Hrd1, 5′-GGAGACUGCCACUACAGUUGUUU-3′, at 10 nM for 48-h 
knockdown; Dharmacon human Sel1L, 5′-GAAACAAACAUUCGAGAUAUU-3′, at 25 nM 
for 48-h knockdown; and human PDI, 5′-CAACUUUGAAGGGGAGGUCTT-3′, and rat 
PDI, 5′-GCGCAUACUUGAGUUCUUUTT-3′, at 75 nM for 72-h knockdown. 
siRNA-resistant PDI construct 
siRNA-resistant WT PDI was generated with KOD Hot Start DNA polymerase (EMD 
Chemicals, Billerica, MA) from mouse WT PDI according to the manufacturer’s protocol. 
The sequences of forward and reverse primers are as follows: forward, 5′-
GCAGCTAGCCCCCATTTGGGACAAGCTCGGCGAAACCTACAAGGATCATGAGAAT
ATC-3′; and reverse, 5′-GATATTCTCATGATCCTTGTAGGTTTCGCCGAGCTTG 
TCCCAAATGGGGGCTAGCTGC-3′. The mutated siRNA-resistant PDI construct was 
confirmed by sequencing. A 2-μg amount of siRNA-resistant PDI plasmid was 
transfected into HEK 293T cells with PEI 24 h posttransfection of the PDI siRNA. 
 
Sucrose cushion sedimentation 
Cells transfected with scrambled or PDI siRNA were lysed in RIPA buffer to generate a 
WCE as described. WCE was centrifuged at 50,000 rpm at 4°C for 20 min using a TLA 
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100 rotor (Beckman, Brea, CA). Half of the resulting supernatant (50 μl) was treated or 
not with DTT (100 mM) for 30 min on ice, layered over an equal volume of a 20% 
sucrose solution, and centrifuged at 75,000 rpm at 4°C for 30 min using the same rotor. 
Top (50 μl) and bottom (50 μl) fractions were separated and subjected to immunoblot 
analyses. 
 
In vitro PDI reduction assay 
PDI was expressed in Escherichia coli strain BL21-Pro and purified as previously 
described (Forster et al., 2009). Purified PDI was aliquoted and stored at −80°C. Akita-
Myc was expressed in PDI-depleted HEK 293T cells for 24 h, followed by cell lysis (50 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES], 150 mM NaCl, 1% 
Triton X-100, 10 mM NEM, and 1 mM PMSF) and overnight immunoprecipitation as 
described. After three washes, Akita-Myc was eluted in 20 μl of a 0.5% SDS buffer at 
room temperature for 30 min, dialyzed, and diluted to 200 μl in a buffer containing 50 
mM HEPES and 150 mM NaCl. Isolated Akita-Myc was incubated in the presence of 1 
mM GSH and 1 mM GSSG with either PDI or PDI alkylated with 25 mM IAA, and the 
reaction was continued at 37°C for 30 min. Samples were separated on a nonreducing 
SDS–PAGE and subjected to immunoblot analysis. 
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RESULTS 
The Hrd1-Sel1L complex promotes ERAD of Akita proinsulin 
To determine whether Akita proinsulin is degraded by ERAD, we first evaluated whether 
Hrd1, the multitransmembrane E3 ubiquitin ligase that is also proposed to function as 
the retrotranslocon (Carvalho et al., 2010; Stein et al., 2014), controls the fate of 
transfected (Myc-tagged) Akita proinsulin. Using cycloheximide chase in 293T cells (and 
in β-cells; see later discussion), we found that Hrd1 knockdown markedly impaired 
degradation of Akita proinsulin (Figure 2-1A; quantified in Figure 2-1B). Of importance, 
depleting Hrd1 (or any other protein described in this study) did not trigger massive ER 
stress, as XBP1 remained largely unspliced under these conditions (Supplemental 
Figure 2-S1A). Our analyses also demonstrated that overexpressing enzymatically 
inactive, dominant-negative Hrd1-C291A (Bernardi et al., 2010) potently stabilized 
Akita proinsulin (Figure 2-1C, top). A smaller degree of inhibition of degradation 
of Akita proinsulin was also observed upon WT Hrd1-Myc overexpression (this is likely 
due to perturbation of the stoichiometric ratio of Hrd1 to its natural binding partners, in 
this way decreasing the efficiency of functional Hrd1-associated complexes). 
Overexpression of WT, mutant Hrd1, or any other construct in this study also did not 
provoke enhanced XBP1 splicing (Supplemental Figure 2-S1B). Together the results 
in Figure 2-1, A–C, indicate that Hrd1 participates in the degradation of Akita proinsulin.  
 
Next we asked whether Sel1L also promotes ERAD of Akita proinsulin. Sel1L is a 
membrane protein that serves as a scaffold to engage ERAD lumenal components 
(Hosokawa et al., 2008; Mueller et al., 2008; Williams et al., 2013), interacts with Hrd1 
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(Mueller et al., 2006), and recruits client substrates to Hrd1 (Bernasconi et al., 2010; 
Stanley et al., 2011). Using a similar cycloheximide-chase protocol, we found that Sel1L 
knockdown also impaired Akita ERAD (Figure 2-1D; quantified in Figure 2-1B), strongly 
implicating the Hrd1-Sel1L membrane complex in the degradation of Akita proinsulin. 
 
Because Akita appears to use the classic ERAD pathway in which the Hrd1-Sel1L 
complex serves as the core membrane component, we asked whether expressing WT 
proinsulin might affect ERAD of Akita, as patients with MIDY harbor one WT copy of the 
proinsulin gene. Indeed, coexpressing superfolder green fluorescent protein–tagged WT 
proinsulin (SfGFP-WT proinsulin, which largely behaves as WT proinsulin; (Haataja et 
al., 2013) significantly impaired degradation of Myc-tagged Akita (Supplemental Figure 
2-S1C, top). This result suggests that the established interaction between WT proinsulin 
and Akita (Liu et al., 2007) can functionally disrupt degradation of Akita, potentially 
exacerbating ER stress, which contributes to MIDY. 
 
p97 facilitates Akita degradation 
Because Hrd1 orients its catalytic E3 ligase domain on the cytosolic surface of the ER 
membrane, retrotranslocated substrates become available for ubiquitination, and the 
ubiquitinated substrates are then extracted into the cytosol—in most cases by the 
cytosolic p97 ATPase (Ye et al., 2001)—before being degraded by cytosolic 
proteasomes. To assess whether p97 participates in ERAD of Akita proinsulin, we 
overexpressed a histidine (His)-tagged WT or ATPase-defective dominant-negative 
version of p97 (QQ-p97). Whereas WT p97 was largely without effect, overexpression 
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of QQ p97-His markedly stabilized Akita proinsulin (Figure 2-2A; quantified in Figure 2-
2B), implicating p97 in the extraction of Akita proinsulin from the ER membrane to the 
cytosol. 
 
Because p97 binds to ubiquitinated substrates, blocking Akita proinsulin extraction into 
the cytosol should cause Akita proinsulin to accumulate as an ubiquitinated species. To 
test this, we cotransfected cells to express Akita proinsulin and QQ p97-His. When Myc-
tagged Akita proinsulin was immunoprecipitated (Figure 2-2C, second from top), the 
polyubiquitinated species accumulated only in cells expressing QQ p97-His (Figure 2-
2C, top). This finding is consistent with the idea that p97 extracts ubiquitinated Akita 
proinsulin from the ER membrane and supports that the classic Hrd1/Sel1L-p97 
pathway promotes ERAD of Akita proinsulin. 
 
PDI promotes Akita degradation 
One major impediment to ERAD is the presence of disulfide bonds that hold the 
substrate in a plicated conformation believed to be incompatible with retrotranslocation. 
Because Akita proinsulin still harbors five cysteine residues in an aberrant disulfide 
configuration (Izumi et al., 2003; Liu et al., 2010a; Liu et al., 2007; Ye et al., 2001) that 
is unknown, enzymatic reduction of disulfide bonds is likely important for its 
retrotranslocation. The major ER-resident oxidoreductase is PDI, which is believed to 
promote oxidative folding of many newly synthesized secretory proteins (Benham, 2012; 
Hatahet and Ruddock, 2009). However, PDI does not appear to facilitate oxidative 
folding of proinsulin in the ER of pancreatic β-cells (Rajpal et al., 2012) and in fact has 
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been implicated in retrotranslocation of certain ERAD substrates and a bacterial toxin 
(Forster et al., 2006; Gillece et al., 1999). Indeed, we found that in cells in which PDI 
was knocked down for 3 d, Akita proinsulin was robustly stabilized (Figure 2-3A; 
quantified in Figure 2-3B). A similar effect on Akita degradation was observed when PDI 
was knocked down for only 2 d (Supplemental Figure 2-S1D). When a small interfering 
RNA (siRNA)–resistant PDI construct was expressed in PDI-knockdown cells, 
degradation of Akita proinsulin was largely restored (Figure 2-3C; quantified in Figure 2-
3B). However, knockdown of ERp57 (Figure 2-3D) or ERdj5 (Figure 2-3E), ER-resident 
oxidoreductases (Appenzeller-Herzog and Ellgaard, 2008; Ushioda et al., 2008), did not 
significantly affect ERAD of Akita proinsulin (quantified in Figure 2-3B). These data 
strongly suggest that ERAD of Akita proinsulin is specifically targeted by PDI. 
 
PDI can function as both an ER molecular chaperone and an ER oxidoreductase (Cai et 
al., 1994). To understand the predominant role of PDI in the ERAD of Akita proinsulin, 
we tested whether knockdown of PDI affected degradation of a proinsulin construct 
lacking all Cys residues (ΔCys-Myc; (Liu et al., 2010a), which is detected intracellularly 
in the presence, but not the absence, of MG132 treatment (Figure 2-3F). Of importance, 
silencing of PDI did not augment the steady-state level of ΔCys-Myc (Figure 2-3F), 
suggesting that the mechanism by which PDI facilitates retrotranslocation of Akita 
proinsulin likely involves interaction with one or more of its cysteine residues. A low 
level of a slower-migrating species (Figure 2-3F, asterisk) that appeared in the PDI-
depleted cells may represent a different folded conformation of this artificial mutant 
proinsulin that persists even under SDS–PAGE, consistent with PDI being a chaperone 
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that unfolds ERAD substrates during retrotranslocation (Gillece et al., 1999). Of interest, 
treating cells with the reducing agent dithiothreitol (DTT) did not alter ΔCys-Myc’s 
steady-state level but did for WT proinsulin-Myc (Figure 2-3G), suggesting that 
degradation of the cysteine-less proinsulin mutant is unaffected by changing the cellular 
redox state. 
 
PDI interacts with, and acts as a reductase for, Akita proinsulin 
To determine whether initiation of ERAD of Akita proinsulin involves a direct interaction 
with PDI, we exploited so-called PDI trap mutants, in which a CXXC thioredoxin motif 
(where C = cysteine and X = any amino acid) is mutated to CXXA. When functioning as 
a reductase, the first cysteine thiol of the CXXC motif attacks a disulfide bond in the 
substrate to form a mixed-disulfide intermediate that is rapidly broken by intradomain 
disulfide pairing with the second CXXC cysteine thiol. These steps reduce the substrate 
disulfide bond while internally oxidizing the thioredoxin motif. However, CXXA trap 
mutants can only cross-link with the substrate and cannot form the intradomain disulfide 
pair, thereby “trapping” mixed disulfide-bonded adducts between PDI and its substrates. 
Because PDI possesses two thioredoxin domains, we used two (FLAG-tagged) trap 
mutants: PDI C56A, to create the first CXXA, and PDI C400A, to create the second 
CXXA. When coexpressed with Akita proinsulin, we found that precipitation of either 
PDI trap mutant recovered disulfide-bonded adducts engaging both PDI and Akita under 
nonreducing conditions (Figure 2-4A, top). As a control, precipitating WT PDI did not 
recover any disulfide-bonded adduct with Akita (Supplemental Figure 2-S2A, compare 
lane 2 to lane 4). One of the main adducts recovered by precipitating PDI C56A had a 
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molecular mass of ∼69 kDa (Figure 2-4A, asterisk) which corresponds precisely to the 
cumulative molecular masses of one PDI (59 kDa) plus one proinsulin (∼10 kDa), 
strongly suggesting a direct disulfide bond rather than binding via intermediary proteins. 
Of interest, precipitation of PDI C400A recovered an adduct of ∼79 kDa (Figure 2-4A, 
triple asterisks), likely representing one PDI molecule plus an Akita dimer. Other 
proinsulin-containing PDI adducts (Figure 2-4A, double and quadruple asterisks) were 
also recovered. By contrast, neither of two different ERp57 trap mutants nor three 
distinct ERp72 trap mutants captured Akita proinsulin (Supplemental Figure 2-S2B), 
strongly suggesting that PDI specifically engages Akita proinsulin. 
 
We also found that the steady-state level of Akita proinsulin was higher in cells 
expressing PDI C56A than with other trap mutants (Supplemental Figure 2-S2B, fourth 
panel), suggesting that such trapping inhibits ERAD of Akita proinsulin. Indeed, 
cycloheximide-chase experiments confirmed that expression of PDI-C56A and PDI-
C400A stabilized Akita proinsulin in comparison to expressing ERp57-C60A or P5 C58A 
(Supplemental Figure 2-S2C, top), where P5 represents yet another PDI family 
member. These analyses provide independent evidence that PDI specifically plays a 
functional role in targeting Akita proinsulin for ERAD. 
 
Because Akita proinsulin lacks a cysteine at position A7, the Cys-B7 lacks its natural 
partner for disulfide bonding. Although this might render Cys-B7 especially available for 
cross-linking with PDI, proinsulin misfolding might involve a variety of disulfide 
mispairings, making other Cys residues more available for adduct formation with PDI. 
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To simplify our analysis, we constructed a family of proinsulin mutants each bearing 
only a single Cys residue. To our surprise, when coexpressed with the PDI-C56A trap 
mutant, two of the six single-Cys proinsulin mutants consistently coprecipitated to a 
greater degree with PDI: a proinsulin construct that harbors only the B19 Cys residue 
(Keep B19), and Keep A11 (Figure 2-3H; quantified in Supplemental Figure 2-S3A). 
However, even when Cys-B7 was the only available unpaired cysteine, the Keep B7 
mutant did not preferentially interact with overexpressed PDI trap mutant (Figure 2-3H; 
quantified in Supplemental Figure 2-S3A). Similarly, when the various proinsulin 
mutants were precipitated (with anti-myc), Keep B7 consistently coprecipitated less PDI 
C56A-FLAG than did Keep B19 or Keep A11 (Supplemental Figure 2-S3B). (Curiously, 
Keep A20 was also able to coprecipitate PDI trap mutant more efficiently than others, 
suggesting that A20 is also a reactive cysteine, although association of Keep A20 with 
PDI trap might affect epitope exposure during immunoprecipitation with anti-FLAG.) 
Together these coprecipitation results support that even when freely available, the 
proinsulin B7 cysteine is disfavored from forming a disulfide bond with PDI; thus it is 
more likely that a complex pattern of intramolecular disulfide mispairing within 
Akita proinsulin accounts for the robust formation of Akita proinsulin adducts with PDI 
(Figure 2-4A). 
 
We then examined the status of Akita in cells with PDI knockdown. When evaluated by 
nonreducing SDS–PAGE, Akita proinsulin in control cells formed high–molecular weight 
(MW) protein complexes and additionally migrated as a disulfide-bonded dimer and 
trimer (Figure 2-4B, top, lane 1). In PDI-knockdown cells (lane 2), the dimer and trimer 
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disappeared and likely entered the high-MW complex. The Akita monomer was 
revealed when the samples were subjected to reducing SDS–PAGE, with the Akita level 
being higher in PDI-depleted cells (Figure 2-4B, second from top, lanes 1 and 2). 
Addition of the proteasome inhibitor MG132 did not restore loss of the Akita dimer or 
trimer observed by nonreducing SDS–PAGE in PDI-depleted cells (Figure 2-4B, top, 
compare lanes 4 and 3), although the steady-state level of low-MW Akita did increase in 
the MG132-treated sample as expected (Figure 2-4B, top, compare lane 3 with lane 1). 
Whereas incubation with the autophagy inhibitor LY294002 (Blommaart et al., 1997) did 
enhance the steady-state level of Akita in control cells (Supplemental Figure 2-S4, 
compare lane 3 to lane 1), this inhibitor clearly did not restore the loss of Akita dimer or 
trimer in PDI-knockdown cells (Supplemental Figure 2-S4, top, compare lanes 4 and 3). 
These results suggest that autophagy is unlikely to be responsible for the 
disappearance of Akita dimer or trimer when PDI is depleted, although this process may 
contribute to quality control of Akita in control cells. Thus the data are consistent with 
the idea that disappearance of dimeric and trimeric Akita in PDI-depleted cells reflects a 
loss of proinsulin reductase activity rather than ERAD or ER-dependent autophagy of 
dimeric and trimeric Akita proinsulin, suggesting that enzymatically active PDI helps to 
limit Akita proinsulin from becoming engaged in high-MW disulfide-linked complexes. 
 
As yet another independent approach, we layered cell extracts expressing Akita 
proinsulin over a 20% sucrose cushion and centrifuged, generating bottom and top 
fractions. The top fraction harbors lower-MW species, likely dimeric and monomeric 
species of Akita proinsulin (Figure 2-4C, top, lane 1), whereas the bottom fraction 
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(Figure 2-4C, top, lane 2) contains Akita proinsulin predominantly in high-MW 
complexes whose sizes are heterogeneous and appear to be larger than ∼55 kDa. In 
control cells, a small portion of Akita proinsulin was recovered in the top fraction, with 
most detected at bottom (Figure 2-4C, top, lanes 1 and 2) whereas in PDI-knockdown 
cells, Akita proinsulin in the top fraction was eliminated (lanes 3 and 4). Of importance, 
when DTT was added to cell extracts before fractionation, even the PDI-knockdown 
cells yielded recovery of Akita proinsulin in the top fraction (Figure 2-4C, second from 
top), mimicking the effect of PDI. In PDI-depleted cells, the combined level of Akita in 
top plus bottom fractions of DTT-treated samples is similar to the Akita level found in the 
bottom fraction only in non–DTT-treated samples (Figure 2-4C, compare second from 
top and top, lanes 3 and 4). As expected, DTT reduced Akita in cell extracts derived 
from PDI-depleted cells, generating Akita monomer and dimer (Supplemental Figure 2-
S5). However, a significant fraction of Akita proinsulin remained in high-MW complexes 
even after reduction by DTT (Figure 2-4C, bottom, lane 4), presumably due to 
noncovalent associations with each other or with other cellular proteins. This is 
consistent with a report suggesting that Akita engages in both covalent and noncovalent 
interactions to remain in the high-MW complexes (Yoshinaga et al., 2005). Our data 
thus strongly suggest that the inability to partition to the top fraction after PDI 
knockdown is due to a lack of reducing power for Akita proinsulin in the ER, supporting 
the notion that PDI acts as a reductase for Akita proinsulin. To assess whether PDI can 
reduce Akita in vitro, we used a modified protocol from the cell-based assay. Akita was 
first isolated from PDI-depleted cells by immunoprecipitation, followed by elution of the 
bound material using SDS and then dialysis to remove the detergent. Isolated Akita was 
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subsequently incubated with bacterially purified PDI (Figure 2-4D, lane 1) or, as a 
negative control, PDI alkylated with iodoacetamide (IAA; IAA-PDI), which should not 
reduce substrates, because its active cysteines are blocked. When this experiment was 
performed under a condition that mimics the ER redox environment (1 mM reduced 
glutathione [GSH] and 1 mM oxidized glutathione [GSSG]; Hwang et al., 1992), PDI but 
not IAA-PDI induced formation of Akita dimer and trimer (Figure 2-4D, lanes 2 and 3; 
the dimer and trimer levels are quantified in the bottom graph), indicating that PDI uses 
its catalytic cysteines to reduce Akita. Note that Akita migrated slightly differently in this 
experiment (Figure 2-4D) compared with the cell-based assay (Figure 2-4B), possibly 
due to the harsh conditions used to isolate Akita in the in vitro assay. Nonetheless, 
these findings support the idea that PDI directly reduces Akita present in high-MW 
disulfide-bonded complexes to generate lower-MW species. 
 
We previously reported that a subset of PDI localizes to the lumenal side of the Hrd1 
membrane complex (Bernardi et al., 2010), which may allow this subset of PDI 
molecules to reduce ERAD substrates more efficiently. To test this, we examined the 
extent to which PDI trap mutants can capture Akita proinsulin when Hrd1 expression is 
silenced. Indeed, upon Hrd1 knockdown, the trapping of Akita proinsulin by PDI-C56A 
and PDI-C400A declined (Figure 2-4E, top). Thus Hrd1 availability enhances the 
efficiency of PDI in engaging Akita to reduce proinsulin disulfide bonds before 
retrotranslocation. 
 
PDI, Hrd1, and p97 promote ERAD of Akita in pancreatic β-cells 
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We next explored the roles of PDI, Hrd1, and p97 in the ERAD of Akita proinsulin in the 
INS-1 832/13 pancreatic β-cell line. Similar to results observed in 293T cells 
(Supplemental Figure 2-S2C), expressing the PDI trap mutants in β-cells slowed 
degradation of Akita proinsulin compared with controls (GFP-FLAG, Figure 2-5A, top; 
the Akita band intensity is quantified in the graph at right). In addition, in INS-1 832/13 
cells, Akita proinsulin was robustly stabilized by dominant-negative Hrd1-C291A but 
more modestly by WT Hrd1 (Figure 2-5B, top; the Akita band intensity is quantified in 
the graph at right). Finally, expressing QQ p97 potently inhibited Akita degradation 
(Figure 2-5C, top; the Akita band intensity is quantified in the graph at right). Together 
these findings indicate that, as in 293T cells, the role of the PDI-Hrd1-p97 axis in the 
ERAD of Akita proinsulin is indeed maintained within the context of pancreatic β-cells. 
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DISCUSSION 
We propose the following model for cellular disposal of Akita mutant proinsulin (Figure 
2-6): disulfide bonds engaged by Akita proinsulin, including intermolecular disulfide 
bonds, are reduced by PDI (step 1), whereupon Akita proinsulin retrotranslocates 
across the ER membrane via the Hrd1/Sel1L membrane complex (indeed, Hrd1 
availability enhances PDI engagement of Akita proinsulin; step 2). Consistent with the 
known enzymatic activity of Hrd1, Akita proinsulin becomes polyubiquitinated upon 
arrival at the cytosolic side of the ER membrane (step 3) before extraction into the 
cytosol by p97, delivering Akita proinsulin to cytosolic proteasomes (step 4). 
 
Degradation of Akita proinsulin engages key elements of the classic ERAD pathway 
Classic ERAD involves the Hrd1-Sel1L membrane complex and the cytosolic p97 
ATPase (Smith et al., 2011; Tsai et al., 2002). The core component is the six-
transmembrane-spanning Hrd1 (Kikkert et al., 2004), which associates with numerous 
adaptor proteins. Hrd1 is believed to serve, first, as the physical conduit for transfer of 
client substrates from the ER lumen to the cytosol (Carvalho et al., 2010; Stein et al., 
2014) and, second, as the major E3 ligase that ubiquitinates ERAD substrates upon 
arrival at the cytosolic face of the ER membrane (Claessen et al., 2012). Using 
cycloheximide chase in conjunction with selective siRNA-mediated knockdown of Hrd1, 
we find that inhibiting Hrd1 function robustly blocks the degradation of Akita proinsulin, 
increasing its steady-state level (Figure 2-1, A and B). We also find that overexpression 
of enzymatically inactive Hrd1 (or, to a much lesser extent, WT Hrd1) similarly produces 
dominant-negative inhibition of Akita proinsulin degradation (Figure 2-1C). The 
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dominant effects of recombinant Hrd1 are believed to arise by competing for natural 
Hrd1 binding partners, thereby impairing the proper stoichiometry and function of Hrd1-
associated protein complexes. Although the results of our WT Hrd1 overexpression 
experiments differ slightly from those reported previously (Allen et al., 2004), our 
conclusions are entirely concordant with the idea that the Hrd1 E3 ligase is involved in 
ERAD of Akita proinsulin, ubiquitinating the substrate when it emerges on the cytosolic 
side of the ER membrane. 
 
Moreover, our findings demonstrate that Sel1L, a membrane binding partner of Hrd1, 
also participates in ERAD of Akita proinsulin (Figure 2-1, B and D). Yet another Hrd1 
interactor, Herp, was also reported to modestly increase the steady-state level 
of Akita proinsulin, suggesting that Herp may also be involved in ERAD of this substrate 
(Hartley et al., 2010). The findings with both Herp and Sel1L support our contention that 
Hrd1 and its interacting partners guide ER-to-cytosol retrotranslocation of misfolded 
proinsulin. 
 
On presentation on the cytosolic side of the ER membrane, polyubiquitinated ERAD 
substrates encounter the cytosolic p97 ATPase, which (in conjunction with its binding 
partners, including Ufd1 and Npl4; (Woodman, 2003)) uses the energy of ATP 
hydrolysis to extract the substrate into the cytosol (Zhang and Ye, 2014). We found that 
overexpressing a catalytically inactive p97 dramatically blocked the degradation 
of Akita proinsulin (Figure 2-2, A and B), supported by a recent report that chemical 
inhibition of p97 modestly inhibits Akita proinsulin degradation in a manner generally 
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similar to that achieved by chemical inhibition of proteasomes (Zhang and Ye, 2014). 
The notion that p97 at the cytosolic face of the ER membrane facilitates the degradation 
of ubiquitinated Akita proinsulin is further demonstrated by the accumulation of 
polyubiquitinated Akita proinsulin in the presence of the dominant-negative p97 mutant 
(Figure 2-2C). Taken together, these findings strongly suggest that p97 mobilizes 
mutant proinsulin into the cytosol for delivery to proteasomes.  
 
PDI’s reductase activity primes Akita proinsulin for ERAD 
A key and surprising finding of our study involves the role of PDI in initiating 
retrotranslocation of Akita proinsulin for ERAD. Such a conclusion is not unreasonable: 
whereas PDI does not serve as an oxidase for native proinsulin disulfide bond formation 
(Rajpal et al., 2012), disulfide isomerase activity may be used to help break nonnative 
disulfide bonds. Moreover, the development of nonremediable misfolding may 
“tag” Akita proinsulin as a potential ERAD substrate. PDI can operate as a chaperone, 
facilitating the unfolding of substrates targeted for ERAD before their retrotranslocation 
(Schelhaas et al., 2007; Tsai et al., 2001), but it is likely that, once selected for ERAD, 
nonnative (and probably even remaining native) proinsulin disulfide bonds must be 
reduced so that the unfolded substrate can thread through the retrotranslocon. 
In the context of genetic mutation of one of the six evolutionarily conserved proinsulin 
cysteine residues, the development of nonremediable proinsulin misfolding is 
guaranteed. An unpaired proinsulin cysteine residue may have the opportunity to attack 
other cysteines within the same proinsulin molecule or other proteins present in the ER 
(including other copies of proinsulin, ER oxidoreductases, or others). PDI appears to 
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preferentially interact with the Cys-B19, Cys-A11, and even Cys-A20 of proinsulin 
(Figure 2-3H and Supplemental Figure S3), but Cys-B7 (the normal disulfide bonding 
partner of Cys-A7) is not a preferential site of adduct formation with PDI.  
 
Thus, Akita proinsulin is likely to be involved in a more complex pattern of disulfide 
mispairing that leads to the generation of PDI adducts. Consistent with this, 
intermolecular disulfide bonds are observed for Akita proinsulin, including both 
nonnative disulfide-linked proinsulin dimers and trimers and disulfide bonds with other 
proteins in high- MW complexes (Izumi et al., 2003; Liu et al., 2010b; Liu et al., 
2007)Figure 2-4), and knockdown of PDI causes loss of the dimers and trimers (Figure 
2-4B) while specifically blocking ERAD of Akita proinsulin (Figure 2-3). 
 
Several new and novel observations support the idea that the role of PDI in the ERAD 
of Akita proinsulin is as a reductase. First, trap mutants that can mimic initial PDI 
reductase activity capture Akita proinsulin in disulfide-linked adducts, including adducts 
that correspond to a direct 1:1 interaction between PDI and Akita proinsulin (Figure 2-
4A). Second, expression of these same PDI trap mutants inhibits degradation 
of Akita proinsulin (Supplemental Figure 2-S2C). Third, PDI knockdown causes simple 
disulfide-bonded Akita dimers to be lost (Figure 2-4B) and to fractionate with high-MW 
complexes, whereas addition of a chemical reductant mimics the effect of PDI (Figure 2-
4C), strongly suggesting that lack of PDI results in a lack of reducing power 
for Akita proinsulin in the ER. Fourth, purified PDI is capable of reducing Akita proinsulin 
in the high-MW complexes to generate Akita dimers and trimers (Figure 2-4D). Thus our 
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collective findings argue strongly that PDI acts as a reductase to initiate 
retrotranslocation of Akita proinsulin. Because many MIDY mutations involve a loss or 
gain of a cysteine that promotes formation of nonnative disulfide bonds (Liu et al., 
2010b), the reductase activity of PDI is also likely to promote ERAD of other MIDY 
mutants. Indeed, the role of PDI in ERAD is far more widespread than for proinsulin 
alone. We note that the classic components of ERAD, including Sel1L, Hrd1, and p97, 
are conserved down to yeast; indeed, it is well established that the yeast Sel1L 
homologue (Hrd3p) recruits lumenal factors for ERAD of substrates that also engage 
yeast Hrd1 (Denic et al., 2006). With this in mind, we note that even in this simple 
eukaryote, the redox activity of PDI has been shown to be important for ERAD of the 
mutant CPY* (Grubb et al., 2012). Thus it is not surprising that our results for ERAD 
of Akita proinsulin in heterologous HEK 293T cells are also obtained in pancreatic β-
cells (Figure 2-5), as ERAD uses common, ancient, essential pathways. 
 
The pathogenesis of MIDY is attributed to the inability of WT proinsulin to exit the ER, 
which is a critical step for normal insulin production (Liu et al., 2010b; Weiss, 2013). 
Because MIDY proinsulin entraps WT proinsulin in the ER, the less abundant the 
misfolded proinsulin, the less is the risk of diabetes (Hodish et al., 2011). In principle, 
restoration of WT proinsulin exit from the ER, resulting in more WT insulin production, 
should be possible if efficient disposal of misfolded proinsulin can be achieved. 
Although there is still much to be learned about the degradation of misfolded proinsulin 
in the ER, exploiting ERAD may serve as a crucial platform for the development of 
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future therapeutic approaches to combat diabetes caused by ER stress–induced β-cell 
failure linked to misfolded proinsulin within the ER. 
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Figure 2-1. The Hrd1-Sel1L complex promotes ERAD of Akita. (A) 293T cells 
expressing Akita-Myc were transfected with a scrambled or Hrd1-specific siRNA. Cells 
were then treated with cycloheximide for the indicated time and harvested, and the 
resulting WCE was analyzed by using the indicated antibodies. (B) The Akita band 
intensity in A and D was quantified with ImageJ (National Institutes of Health, Bethesda, 
MD). Data represent mean ± SD of at least three independent experiments. (C) As in A, 
except that cells were transfected with GFP-FLAG, WT Hrd1-Myc, or C291A Hrd1-Myc 
construct. (D) As in A, except cells were transfected with a siRNA against Sel1L. The 
black vertical line indicates that an intervening lane from the same immunoblot has 
been spliced out. 
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Figure 2-2. p97 facilitates Akita degradation. (A) As in Figure 2-1C, except that 293T 
cells were transfected with WT p97-His or QQ p97-His. (B) As in Figure 2-1B, except 
that the Akita band intensity in A is quantified. (C) 293T cells expressing Akita-Myc or 
not were transfected with an empty vector or QQ p97-His as indicated. Cells were lysed 
in a RIPA buffer and Akita immunoprecipitated from the resulting WCE using a Myc 
antibody. The precipitated material was subjected to SDS–PAGE and immunoblotted 
with the indicated antibodies. The WCE was also immunoblotted. 
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Figure 2-3. PDI exerts a key role in regulating Akita degradation. (A) As in Figure 2-
1A, except that 293T cells were transfected with a PDI-specific siRNA for 3 d. (B) As 
in Figure 2-1C, except that the Akita band intensity in A and C–E are quantified. (C) As 
in A, except where indicated cells transfected with a PDI-specific siRNA for 3 d were 
cotransfected with a PDI construct resistant to the PDI-specific siRNA. (D) As in A, 
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except hat cells were transfected with an ERp57-specific siRNA. (E) As in A, except that 
cells were transfected with an ERdj5-specific siRNA. (F) 293T cells expressing either a 
control or PDI-specific siRNA were cotransfected with ΔCys-Myc and treated or not with 
MG132 as indicated. (G) Cells expressing WT proinsulin-Myc or ΔCys-Myc were treated 
with DTT (10 μM) in the presence of MG132 and the WCE analyzed as in F. (H) 293T 
cells expressing the indicated Myc-tagged mutant proinsulins were cotransfected with 
PDI C56A-FLAG. The cells were lysed and immunoprecipitated with M2 FLAG antibody-
conjugated beads, analyzed by reducing SDS–PAGE, and immunoblotted using the 
appropriate antibodies. The WCE was also directly immunoblotted with anti-Myc or anti-
FLAG antibodies. pTarget was the plasmid used as a control for the mutant proinsulin 
constructs. 
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Figure 2-4. PDI acts as a reductase against Akita. (A) 293T cells 
expressing Akita were transfected with or without PDI C56A-FLAG or PDI C400A-
FLAG. Tagged PDI proteins were immunoprecipitated from the resulting WCE using a 
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FLAG antibody. The precipitated material was subjected to nonreducing or reducing 
SDS–PAGE as indicated and immunoblotted using the appropriate antibodies. The 
WCE was also immunoblotted with a Myc antibody. (B) 293T cells expressing Akita and 
transfected with either a scrambled or PDI-specific siRNA were treated with or without 
MG132. The resulting WCE was subjected to nonreducing or reducing SDS–PAGE as 
indicated and immunoblotted using the indicated antibodies. The black vertical line 
indicates that an intervening lane from the same immunoblot has been spliced out. (C) 
Lanes 1–4, WCE in B was treated with or without DTT, layered over a 20% sucrose 
cushion, and centrifuged. The top and bottom fractions were separated and subjected to 
SDS–PAGE, followed by immunoblotting using a Myc antibody. Lanes 5 and 6, WCE 
was subjected to SDS–PAGE, followed by immunoblotting using the indicated 
antibodies. (D) His-tagged PDI purified from bacteria is shown in the Coomassie gel. 
Immunoprecipitated Akita-Myc from PDI-knockdown cells was incubated with PDI or 
IAA-modified PDI in the presence of 1 mM GSH and 1 mM GSSG, and the samples 
were subjected to nonreducing SDS–PAGE, followed by immunoblotting with a Myc 
antibody. Bottom graph, the intensity level of Akita dimer and trimer was quantified by 
ImageJ. Data represent the mean ± SD of three independent experiments. The black 
vertical line indicates that an intervening lane from the same immunoblot has been 
spliced out. (E) Cells expressing Akita transfected with a scrambled or Hrd1-specific 
siRNA were cotransfected with either PDI C56A-FLAG or PDI C400A-FLAG. The ability 
of tagged PDI protein to interact with Akita was analyzed as in A. 
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Figure 2-5. PDI, Hrd1, and p97 promote ERAD of Akita in pancreatic β-cells. (A) As 
in Supplemental Figure 2-S2C, except that rat pancreatic INS-1 832/13 β-cells were 
used and GFP-FLAG was expressed instead of ERp57 C60A-FLAG. The Akita band 
intensity is quantified as in Figure 2-1B. (B) As in Figure 2-1C, except that the 
experiment was performed in INS-1 832/13 β-cells and GFP-FLAG was transfected 
instead of vector. The Akita band intensity is quantified as in Figure 2-1B. (C) As 
in Figure 2-2A, except that the experiment was performed in INS-1 832/13 β-cells and 
GFP-FLAG was transfected instead of vector. The Akita band intensity is quantified as 
in Figure 2-1B. 
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Figure 2-6. Model depicting ERAD of Akita. To dispose of Akita via the ERAD 
pathway, PDI reduces the disulfide bonds in this mutant proinsulin to initiate its 
retrotranslocation into the cytosol (step 1). The precise pairing of disulfide bonds 
in Akita proinsulin is not known. In the second step, Akita retrotranslocates across the 
ER membrane by using the Hrd1/Sel1L membrane complex (step 2). Once it is 
presented to the cytosol, Akita becomes polyubiquitinated using Hrd1’s catalytic activity 
(step 3). In the final step, p97 propels polyubiquitinated Akita into the cytosol, targeting it 
to the proteasome for degradation (step 4). 
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Figure 2-S1. Additional characterization under different knockdown and 
overexpression conditions. A. Induction of XBP1 splicing was analyzed in cells 
transfected with the indicated siRNA for the indicated number of days. DTT-treated cells 
were used as a positive control. B. As in A, except cells were transfected with the 
indicated construct. C. As in Figure 2-1C, except cells were transfected with either 
SfGFP-WT proinsulin or GFPFLAG. D. Akita degradation was analyzed as in Figure 2-
3A, except cells were transfected with the PDI specific siRNA for only 2 days. 
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Figure 2-S2. PDI trap mutants selectively capture Akita and block its degradation. 
A. As in 2-4A, expect WT PDI-FLAG was used. B. As in 2-4A, except the indicated 
ERp57 or ERp72 trap mutant constructs were used. C. As in 2-2A, except the indicated 
PDI, ERp57, or p5 trap mutant constructs was used. 
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Figure 2-S3. The B7 cysteine residue in Akita does not preferentially form a 
disulfide bond with PDI. A. The level of mutant proinsulin-Myc in 2-3H was quantified 
using ImageJ (NIH). B. 293T cells expressing the indicated Myc-tagged mutant 
proinsulin were co-transfected with PDI C56A-FLAG. The cells were lysed and 
immunoprecipitated with anti-Myc (9E10) antibody, analyzed by reducing SDS-PAGE, 
and immunoblotted using the appropriate antibodies. The level of PDI C56A-FLAG was 
quantified using ImageJ (NIH). 
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Figure 2-S4. Autophagy inhibition does not prevent loss of Akita dimer and trimer 
in PDI-depleted cells. As in Figure 2-4B, except cells were treated with 20 µM of the 
autophagy inhibitor LY294002 for 2 h instead of MG132. 
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Figure 2-S5. DTT reduces Akita. A cell extract derived from PDI-depleted cells was 
treated with or without DTT, and analyzed by non-reducing SDS-PAGE. 
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INTRODUCTION 
Insulin is a peptide hormone secreted by pancreatic β-cells that controls blood glucose 
levels (Hales, 1971). Insulin biosynthesis begins when the precursor preproinsulin is 
translocated into the endoplasmic reticulum (ER) (Steiner et al., 1967). This precursor 
harbors an N-terminal signal sequence, followed sequentially by the B chain, connecting 
C-peptide, and A chain. Upon translocation into the ER, the signal sequence is excised, 
forming proinsulin (Steiner et al., 1967). Folding of proinsulin to its native conformation 
in the ER is coordinated with the formation of three highly conserved disulfide bonds (B 
chain 7th residue to A chain 7th residue, called the B7-A7 disulfide bond, plus the B19-
A20 and A6-A11 disulfide bonds). When properly folded and oxidized, proinsulin is 
transported from the ER via the Golgi complex to immature secretory granules. Upon 
proteolytic excision of the C-peptide in this organelle, the B and A chains remain 
attached via their two interchain disulfide bonds, representing bioactive insulin that is 
poised for secretion to the bloodstream via exocytosis of secretory granules
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Recently over 29 missense mutations in the human insulin gene have been identified to 
cause an autosomal-dominant disease called mutant INS gene–induced diabetes of 
youth (MIDY) (Liu et al., 2010b; Liu et al., 2007; Stoy et al., 2007; Weiss, 2013). 
Whereas most MIDY proinsulin mutants are misfolded and cannot form bioactive 
insulin, the initial onset of clinical insulin deficiency appears to be driven by dominant 
interference with the folding of wild-type (WT) proinsulin, impairing its ER exit and 
thereby limiting the production and eventual secretion of bioactive insulin. A decrease in 
insulin secretion causes hyperglycemia, which may provoke β-cells to further upregulate 
proinsulin synthesis (including the products of both mutant and WT alleles). 
Concomitant with proinsulin misfolding is ER stress and diabetes with eventual β-cell 
demise. 
 
The most-studied MIDY mutant is Akita proinsulin, in which mutation of the A7 cysteine 
to tyrosine, so-called C(A7)Y, leaves an unpaired cysteine partner at the B7 position 
(Wang et al., 1999). This unpaired cysteine can potentially form an intermolecular 
disulfide bond with another misfolded Akita molecule or with WT proinsulin, generating 
both disulfide-bonded and noncovalent high–molecular weight (MW) protein complexes 
that are likely to engage ER resident proteins such as molecular chaperones. As a 
result of entry into such complexes, efficient ER exit of WT proinsulin is prevented, 
leading to the disease (Liu et al., 2010b; Liu et al., 2007; Weiss, 2013). The extent of 
blockade of WT proinsulin is directly related to the relative abundance of the mutant 
proinsulin protein (Liu et al., 2007; Weiss, 2013). For this reason, we postulate that 
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selective disposal of Akita proinsulin might facilitate the folding and export of the WT 
counterpart, thereby enhancing insulin secretion. 
 
Because approximately one-third of cellular proteins are synthesized in the ER, it is not 
surprising that this organelle harbors rigorous protein quality control processes. One 
such process is called ER-associated degradation (ERAD), in which misfolded ER 
clients are retrotranslocated to the cytosol, where they are degraded by proteasomes 
(Ruggiano et al., 2014; Smith et al., 2011; Tsai et al., 2002). Recently, our laboratory 
and others identified several components of the ERAD machinery that facilitate 
degradation of Akita proinsulin (Allen et al., 2004), including the ER membrane-bound 
E3 ubiquitin ligase Hrd1, its membrane-binding partner Sel1L, and the cytosolic AAA+ 
ATPase p97 (He et al., 2015). We also reported that the ER luminal protein disulfide 
isomerase (PDI) may participate in reducing disulfide bonds that can help to liberate 
Akita proinsulin from high-MW protein complexes, generating smaller dimeric/trimeric 
species that are competent for retrotranslocation (He et al., 2015); another PDI family 
member, PDIA6 (encoding the P5 protein), may also play a role in this process (Gorasia 
et al., 2016). Whether other ER luminal components can help to drive Akita proinsulin 
along the ERAD pathway, and whether enhanced degradation of Akita proinsulin 
degradation can impact WT proinsulin export, are unknown. 
 
Here we demonstrate that the ER luminal chaperone Grp170, an atypical member of the 
Hsp70 superfamily (Behnke et al., 2015), promotes the degradation of Akita proinsulin. 
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We show that Grp170 shifts the balance of high-MW oligomers bearing Akita proinsulin 
toward smaller oligomeric species that are capable of undergoing ERAD. Importantly, 
whereas WT proinsulin is trapped alongside the mutant in these high-MW protein 
complexes, overexpressing Grp170 can liberate WT proinsulin, enhancing Akita 
degradation and increasing WT insulin secretion. Hence, the ability to improve insulin 
secretion by selectively triaging a MIDY mutant suggests a rational strategy to treat the 
disease by rectifying the underlying MIDY defect. 
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RESEARCH DESIGN AND METHODS 
Antibodies 
The antibodies used were as follows: rabbit anti-Myc (Immunology Consultants 
Laboratories); mouse anti-PDI and rabbit anti-Hsp90 (Santa Cruz Biotechnology); rabbit 
anti-FLAG, and mouse/rabbit horseradish peroxidase secondary antibodies (Sigma-
Aldrich); rabbit anti-GFP (green fluorescent protein; Proteintech); rabbit anti-
Orp150/Grp170 (Abcam); rabbit anti-Sil1 (GeneTex); and mouse anti-VCP/p97 (Thermo 
Scientific). Chemicals were from Sigma-Aldrich except when noted otherwise. 
Phenylmethylsulfonyl fluoride (PMSF) was from Acros Organics. DMEM, RPMI 1640 
medium, and other cell culture reagents were from Life Technologies. Plasmids 
encoding Myc-epitope–tagged human C(A7)Y Akita mutant proinsulin (Akita-Myc), WT 
proinsulin-Myc, and WT proinsulin-superfolder GFP (sfGFP) were previously described 
(Haataja et al., 2013; Liu et al., 2010a). Human PDI trap mutant was a gift from T. 
Rapoport (Harvard University, Cambridge, MA). The INS-1 832/13 β-cell line was a gift 
from Christopher Newgard (University of Texas Southwestern Medical Center, Dallas, 
TX). Subtilase cytotoxin complex (SubAB) and mutant SubAA272B were expressed in 
recombinant Escherichia coli with a B-subunit COOH-terminal His6 tag and purified by 
Ni-NTA chromatography, as previously described (Paton et al., 2004). 
 
Cell Culture, Plasmid Transfection, Cycloheximide Chase, Immunoprecipitation, 
and Immunoblotting 
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Rat INS-1 832/13, human HEK 293T cells, and their derivative cell line (Tet-induced 
Grp170 expression cell line) were cultured at 37°C. Cells were seeded 1 day before 
transfection of 0.25–2 μg of plasmid DNA using polyethylenimine or Lipofectamine 2000 
(Invitrogen). Twenty-four hours after transfection, cells were treated with cycloheximide 
(100 μg/mL) and chased for 0, 2, 4, and 6 h. Cells were harvested in PBS containing 10 
mmol/L N-ethylmaleimide (NEM). For immunoprecipitation (IP), cells were lysed in 400 
μL of radioimmunoprecipitation assay (RIPA) buffer (Tris-HCl, pH 7.5, 150 mmol/L 
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with 10 mmol/L 
NEM and 1 mmol/L PMSF. Cells were incubated on ice for 10 min and centrifuged, and 
the resulting whole-cell extract (WCE) was incubated with antibody (1:200) at 4°C for 24 
h, followed by 2 h of incubation with protein A/G-agarose beads at 4°C. Beads were 
washed and boiled in SDS sample buffer with or without 100 mmol/L dithiothreitol. For 
immunoblot analyses, cells were lysed in 100 μL of RIPA buffer to generate the WCE, 
which was boiled in SDS sample buffer with 100 mmol/L dithiothreitol. Samples were 
resolved on 8–15% SDS-PAGE, transferred to nitrocellulose, and immunoblotted with 
specific primary and secondary antibodies. 
 
Small Interfering RNA Knockdown of Grp170, Sil1, and PDI 
Small interfering RNA (siRNA) was transfected into cells using RNAi MAX (Invitrogen), 
and cells were chased and harvested 48–72 h after treatment. Sequences of the 
siRNAs are as follows: 
PDI siRNA: (5′-CAACUUUGAAGGGGAGGUCTT-3′; Invitrogen), 
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Grp170 siRNA 1: (5′-GCUCAAUAAGGCCAAGUUUTddT-3′; Invitrogen), 
Grp170 siRNA 2: (5′-GCCUUUAAAGUGAAGCCAUdTdT-3′; Invitrogen), 
Grp170 siRNA 3: (5′-GCCUUUGAAGAACGACGAAdTdT-3′; Invitrogen), 
Sil1 siRNA: (5′-GCUGAUCAACAAGUUCAAUdTdT-3′; Invitrogen). 
 
Proinsulin Secretion Assay 
A plasmid encoding WT proinsulin tagged with sfGFP in the C-peptide was transfected 
into Grp170-inducible and rat INS-1 832/13 β-cells using polyethylenimine and 
Lipofectamine 2000 (Invitrogen), respectively. For the inducible cell lines, 1 µg/mL 
tetracycline (Tet) was added at the time of transfection. Six hours after transfection, the 
medium was replaced with 500 µL fresh medium supplemented with Tet and incubated 
for 16 h. The medium was collected in a 1.7-mL tube with 6× SDS reducing sample 
buffer and boiled. Cells were also harvested in PBS, lysed in RIPA buffer, and 
denatured in reducing SDS sample buffer. These samples were analyzed by 
immunoblotting. 
 
Sucrose Gradient Fractionation 
To prepare the lysate, cells were harvested in 10 mL PBS supplemented with 10 
mmol/L NEM and pelleted at 1,500g for 5 min. Cell pellets were lysed in RIPA buffer 
supplemented with 10 mmol/L NEM and 1 mmol/L PMSF and incubated on ice. After a 
first centrifugation at 16,000g for 10 min, the resulting supernatant was further cleared 
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by ultracentrifugation at 50,000 rpm (100,000g) for 20 min. The resulting supernatant 
was layered over a 10–50% discontinuous sucrose gradient and centrifuged using a 
Beckman SW50.1 rotor at 29,000 rpm for 24 h at 4°C. After centrifugation, tubes were 
removed and 50-µL fractions were collected. 
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RESULTS 
Grp170 Knockdown Impairs Degradation of Akita Proinsulin With Depletion of 
Oligomeric Forms 
Grp170 was recently identified as a novel ER luminal factor promoting ERAD of 
misfolded ER clients (Inoue and Tsai, 2016), as well as toxic agents that hijack the 
ERAD pathway to cause infection (Inoue and Tsai, 2015; Williams et al., 2015). We 
therefore tested whether this chaperone promotes the degradation of Akita proinsulin 
using a cycloheximide chase approach in HEK 293T cells transiently expressing Akita-
Myc, where the tag is appended within the C-peptide domain. We found that Grp170 
knockdown using two different siRNAs targeted against Grp170 (siRNA 1 and 2) (Fig. 3-
1A, second panel) significantly impaired the degradation of Akita-Myc when compared 
with cells treated with the control siRNA (scrambled) (Fig. 1A, top panel [the intensity of 
the Akita-Myc band is quantified in Fig. 3-1B]). Because Grp170 can act as a nucleotide 
exchange factor (NEF) against the ER luminal BiP ATPase (Behnke et al., 2015), we 
asked whether the other ER-resident NEF called Sil1 also facilitates Akita-Myc 
degradation and found that it did not (Fig. 3-1C, top panel [quantified in Fig. 3-1B]). 
These results suggest Grp170 specifically promotes degradation of Akita proinsulin. 
 
Using nonreducing SDS-PAGE, we previously reported that Akita-Myc forms high-MW 
protein complexes as well as smaller dimeric/trimeric oligomeric species (He et al., 
2015). In cells with siRNA-mediated knockdown of Grp170, these smaller Akita-Myc 
oligomers were depleted when compared with the control (Fig. 3-2A, top panel; 
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quantified in graph). However, under reducing conditions, in cells with siRNA-mediated 
knockdown of Grp170, the total level of Akita-Myc was actually increased (Fig. 3-2A, 
bottom panel). One plausible explanation for these results is that in the absence of 
Grp170, smaller oligomeric species of Akita proinsulin may be further shifted into 
higher-MW protein complexes. To evaluate this possibility, extracts from control or 
Grp170-depleted cells expressing Akita-Myc were sedimented on a 10–50% 
discontinuous sucrose gradient. Individual fractions were collected and subjected to 
reducing SDS-PAGE followed by immunoblotting using an antibody against Myc. 
Whereas Akita-Myc distributed throughout the entire gradient under the control 
condition, in Grp170-depleted cells the mutant proinsulin accumulated in fractions 
corresponding to high-MW protein species (Fig. 3-2B, compare top and second panels; 
the Akita-Myc band intensity is quantified in the graph below). These results are 
consistent with the notion that when Grp170 is knocked down, smaller oligomeric 
species of Akita proinsulin are further shifted into high-MW protein complexes. Our 
findings support the hypothesis that Grp170 promotes degradation by shifting the 
balance of Akita proinsulin in favor of lower MW (smaller) species that are competent to 
undergo ERAD (He et al., 2015). 
 
Overexpressing Grp170 Facilitates Degradation of Akita Proinsulin 
To complement the loss-of-function (knockdown) approach, we used a gain-of-function 
(overexpression) strategy to further assess the role of Grp170 in the degradation of 
Akita proinsulin. We found that overexpressing Grp170-FLAG (Fig. 3-3A, second panel) 
stimulated the time-dependent disposal of Akita-Myc (Fig. 3-3A, top panel [quantified in 
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Fig. 3-3B]) but also lowered the steady-state level of Akita proinsulin even at the start of 
the experiment (Fig. 3-3A, top panel, zero time). The Grp170-induced degradation of 
Akita proinsulin is ERAD dependent because blocking ERAD by expressing the 
ATPase-defective p97 (QQ p97-His) (He et al., 2015; Ye et al., 2001) but not WT p97 
prevented the overexpressed Grp170 from stimulating Akita degradation (Fig. 3-3C, top 
panel [Akita-Myc band intensity is quantified in Fig. 3-3B]). These data strongly suggest 
that Grp170 triggers Akita proinsulin degradation through the classic ERAD pathway. 
 
To test the hypothesis that Grp170 promotes ERAD by shifting Akita proinsulin toward 
low-MW (smaller) species, we treated both control cells and cells overexpressing 
Grp170 with the proteasome inhibitor MG132 to block ERAD downstream in order to 
detect the oligomeric state of the accumulated Akita-Myc (omission of MG132 resulted 
in insufficient Akita-Myc accumulation to allow for such analysis; Fig. 3-3A, top panel). 
By sucrose gradient centrifugation, Akita-Myc in the control cell extract was found fairly 
evenly throughout the entire gradient (Fig. 3-3D, top panel and quantified below). 
Strikingly, in cells overexpressing Grp170, the distribution of Akita-Myc was shifted 
toward fractions 3–4, corresponding to low-MW (smaller) species (with an apparent 
decrease in fractions 6–8 corresponding to larger Akita-Myc oligomers) (Fig. 3-3D, 
bottom panel and quantified below). Thus, these gain-of-function studies also support 
the hypothesis that Grp170 facilitates ERAD of Akita proinsulin by favoring the 
generation of ERAD-competent low-MW (smaller) species. 
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Grp170 Promotes the Interaction of PDI With Akita Proinsulin 
We envision that to promote an increase in ERAD-competent low-MW Akita proinsulin, 
Grp170 is likely to bind to the ERAD substrate. In cells expressing Akita-Myc and 
Grp170-FLAG (or a control protein [GFP-FLAG]), immunoprecipitating Grp170-FLAG 
but not GFP-FLAG coprecipitated Akita-Myc (Fig. 3-4A, top panel, compare lane 2 to 1). 
Endogenous BiP also coprecipitated with Grp170-FLAG but not GFP-FLAG (Fig. 3-4A, 
second panel). These findings are consistent with the established role of Grp170 as a 
NEF for BiP (Behnke et al., 2015). However, regardless of whether cells were 
intoxicated with the SubAB toxin that cleaves BiP or an inactive mutant SubAA272B that 
cannot degrade BiP (Fig. 3-4A, fifth panel, compare lane 3 to 2) (Paton et al., 2006), the 
Grp170-Akita proinsulin interaction persisted (Fig. 3-4A, top panel; quantified in graph), 
indicating that the Grp170-Akita proinsulin association is BiP independent. 
 
Because PDI, an ER oxidoreductase, also interacts with Akita proinsulin (He et al., 
2015), we examined the relationship between the respective PDI and Grp170 
associations with Akita-Myc. We found that in cells coexpresssing Grp170-FLAG, 
knockdown of PDI caused Akita proinsulin association with Grp170 to be augmented 
(Fig. 3-4B, top panel, compare lane 3 to 2; quantified in graph). By contrast, in cells with 
knockdown of Grp170, the interaction of Akita proinsulin with a PDI “trap mutant” (that 
forms mixed disulfide adducts with Akita proinsulin) (He et al., 2015) diminished (Fig. 3-
4C, top panel; quantified in graph). Thus, the efficiency of PDI interaction with Akita 
proinsulin appears to be promoted by the availability of Grp170, whereas the efficiency 
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of Grp170 interaction with Akita proinsulin is not promoted (and might even be 
competed) by the availability of PDI. 
 
Grp170-Dependent Restoration of Small Oligomeric Forms Promotes ERAD of 
Akita Proinsulin Concomitant With ER Export of Coexpressed WT Proinsulin 
Because WT and mutant proinsulins are coexpressed in the disease known as MIDY, 
we asked whether Grp170 displays preferential binding to either of these two proteins. 
In cells coexpressing Grp170-FLAG and either WT proinsulin-Myc or Akita-Myc (where 
the tag is incorporated within the C-peptide domain), precipitating equal amounts of 
Grp170-FLAG pulled down more Akita than WT proinsulin (Fig. 3-5A, top panel, 
compare lane 2 to 1). This preference is even more exaggerated when considering the 
lower abundance of Akita proinsulin levels in these cells (Fig. 3-5A, third panel, 
compare lane 2 to 1). Even when cells were treated with brefeldin A to block 
anterograde cargo exit from the ER (Klausner et al., 1992), the Grp170 interaction with 
ER-entrapped WT proinsulin was not enhanced (Fig. 3-5A, top panel, compare lane 3 to 
1). Taken together, these results indicate that Grp170 intrinsically favors the misfolded 
Akita proinsulin over WT proinsulin. 
 
Because Grp170 stimulates ERAD of Akita proinsulin (Fig. 3-3A and B), the preferential 
association of Grp170 with Akita proinsulin might allow WT proinsulin to escape from 
the ER en route to subsequent secretion. To test this, we used a 293T cell line with 
inducible expression of Grp170-FLAG (Inoue and Tsai, 2016). Conveniently, because 
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293T cells do not express prohormone convertases or secretory granules involved in 
the endoproteolytic conversion of proinsulin to insulin, proinsulin export from the ER of 
these cells can be monitored by the secretion of proinsulin itself. In these cells, transient 
expression of WT proinsulin-sfGFP (where sfGFP is incorporated within the C-peptide 
domain) was followed by induction of Grp170-FLAG via the addition of Tet. Tet addition 
did not affect WT proinsulin-sfGFP secretion (Fig. 3-5B, top panel [quantified in Fig. 3-
5C]). As expected (Liu et al., 2010b; Liu et al., 2007), coexpression of Akita-Myc 
inhibited the secretion of WT proinsulin-sfGFP (Fig. 3-5B, top panel [quantified in Fig. 3-
5C]). Strikingly, Grp170-FLAG induction in cells expressing Akita-Myc restored the 
secretory trafficking of WT proinsulin-sfGFP (Fig. 3-5B, top panel [quantified in Fig. 3-
5C]). Overcoming this dominant-negative behavior of Akita proinsulin on WT proinsulin 
by Grp170 requires an intact ERAD pathway, as WT proinsulin rescue by Grp170 could 
no longer be observed in cells coexpressing QQ p97-His (Fig. 3-5D, lane 3). These 
findings strongly suggest that the rescue of WT proinsulin export by Grp170 requires 
active ERAD and is mediated in parallel with the selective degradation Akita proinsulin. 
 
In the absence of WT proinsulin, Akita proinsulin can form high-MW protein complexes. 
In this condition, overexpressing Grp170 stimulates Akita proinsulin degradation by 
increasing the abundance of ERAD-competent low-MW (smaller) species (Fig. 3-3). 
When WT proinsulin is coexpressed with Akita, WT proinsulin becomes entrapped 
along with Akita proinsulin in the ER (He et al., 2015; Liu et al., 2010b). Thus, we 
hypothesize that increased activity of Grp170 should not only stimulate the degradation 
of Akita proinsulin, but WT proinsulin may also be disconnected from high-MW protein 
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complexes, enhancing the export of WT proinsulin from the ER. We used sucrose 
sedimentation analysis to evaluate changes in the oligomeric state of WT proinsulin 
upon coexpression with Akita proinsulin, along with the effect of induced expression of 
Grp170. When expressed by itself, WT proinsulin-sfGFP was found in fractions 
corresponding to low-MW oligomeric species (Fig. 3-5E, top panel; quantified in the 
graph below); induction of Grp170 did not affect its oligomeric state (Fig. 3-5E, second 
panel; quantified below). As expected, coexpressing Akita-Myc caused a pool of WT 
proinsulin-sfGFP to migrate into higher-MW fractions (Fig. 3-5E, third panel; quantified 
below). Importantly, upon Grp170 induction, a significant pool (≥25%) of WT proinsulin-
sfGFP was shifted out of the higher MW fractions back to its original smaller oligomeric 
state (Fig. 3-5E, fourth panel; quantified below). These findings suggest that increased 
Grp170 activity helps to increase the abundance of low-MW forms of both Akita 
proinsulin and WT proinsulin, thereby facilitating ERAD of Akita proinsulin while 
concomitantly facilitating anterograde transport of WT proinsulin. 
 
The Role of Grp170 in Akita Proinsulin Degradation and WT Proinsulin Secretion 
in β-Cells 
Because the foregoing experiments were executed in a heterologous system, we asked 
whether these data could be recapitulated in the context of pancreatic β-cells. For this, 
we used INS1 832/13 (rat-derived) β-cells in which Akita-Myc is transiently expressed. 
Whereas depleting Grp170 decreased Akita-Myc degradation (Fig. 3-6A, top panel 
[quantified in Fig. 3-6B]), overexpressing Grp170-FLAG enhanced its degradation (Fig. 
3-6C, top panel [quantified in Fig. 3-6D]). 
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To measure insulin secretion from β-cells, we expressed WT proinsulin-sfGFP and 
subsequently monitored the C-peptide-sfGFP released to the extracellular medium 
(using high-sensitivity immunoblotting with anti-GFP antibody). Because β-cells harbor 
prohormone convertases, the intervening C-peptide-sfGFP is excised from proinsulin, 
costored in secretory granules, and secreted in parallel with insulin (Haataja et al., 
2013; Zhu et al., 2016). In these cells, we found that coexpressing Akita-Myc with WT 
proinsulin-sfGFP blocked secretion of the C-peptide-sfGFP, as anticipated (Fig. 3-6E, 
top panel [quantified in Fig. 3-6F]). Remarkably, additional expression of Grp170-FLAG 
decreased the intracellular abundance of Akita-Myc and restored C-peptide-sfGFP 
secretion (Fig. 3-6E, top panel [quantified in Fig. 3-6F]). Hence, in a more 
physiologically relevant cellular context, these findings confirm that enhancing Grp170 
activity allows for facilitating the ERAD of Akita proinsulin while concomitantly facilitating 
anterograde transport of WT proinsulin with the production of insulin (and C-peptide-
sfGFP), leading to enhanced insulin (and C-peptide-sfGFP) secretion. 
 
As all “Grps” (glucose-regulated proteins) are induced during stress, we asked whether 
our overexpression system was comparable in Grp170 expression to Akita mouse 
islets. For this, we used different pharmacological and physiological conditions to 
examine the expression of Grp170. Interestingly, Akita-Myc expression in HEK 293T 
cells drives Grp170 protein expression to levels similar to Akita mouse islets (Fig. 3-6G, 
top panel, compare lanes 3 to 7), clearly indicating that Grp170 levels are upregulated 
by misfolded proinsulin entrapped in the ER. Importantly, overexpression of Grp170 in 
84 
 
HEK 293T cells enabled us to achieve protein levels that are slightly higher than the 
endogenous upregulation of Grp170 in Akita mouse islets (Fig. 3-6G, compare lanes 4 
to 7). Indeed, it is this overexpression in 293T cells compared with the physiological ER 
stress response that drives the degradation of the Akita proinsulin mutant, supporting 
our central premise that it will require more than merely increasing Grp170 to ER stress 
levels in order to enhance degradation of the Akita proinsulin mutant in MIDY. 
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DISCUSSION 
In this discussion, we address two main points developed by the current studies. First, 
we have identified a novel ER luminal component that promotes degradation of a 
misfolded proinsulin. Second, we highlight a principle that may be exploited to rectify the 
protein-misfolding problem underlying the disease known as MIDY. 
 
Function of Grp170 in ERAD of Akita Proinsulin 
First, on the basis of our studies conducted both in 293T cells and in a pancreatic β-cell 
line, we propose that the ER-resident chaperone Grp170 promotes ERAD of Akita 
proinsulin by shifting the balance of Akita proinsulin in favor of smaller oligomeric 
species that are competent to undergo ERAD (Fig. 3-6H). Grp170 may accomplish this 
feat by using two different potential mechanisms. In one mechanism, Grp170 binds to 
the smaller species of Akita proinsulin in the ER, preventing their further association in 
high-MW complexes; these smaller species are more efficiently targeted for destruction 
along the ERAD pathway. Indeed, a recent study (Behnke et al., 2016) suggests that 
Grp170 preferentially recognizes amino acids in clients that are predisposed to go on to 
aggregation. Whether Grp170 shields aggregation-prone residues within smaller 
species of Akita proinsulin remains to be tested. If this is the case, we speculate that the 
long COOH-terminal “holdase” domain of Grp170, which serves a role in substrate 
binding (Behnke et al., 2015; Behnke and Hendershot, 2014), may be responsible for 
interacting with these amino acids. Because Grp170 was shown to associate with the 
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core ERAD membrane machinery via binding directly to Sel1L (Inoue and Tsai, 2016), 
Grp170 can execute its function proximal to the retrotranslocation site. This scenario 
may potentially allow Grp170 to present smaller species of Akita proinsulin for ER-to-
cytosol translocation, thereby enhancing the efficiency of ERAD. 
 
In an alternative mechanism, Grp170 associates with high-MW aggregates of Akita 
proinsulin and dissociates small oligomeric species from their entrapment within the 
high-MW protein complexes by untangling the noncovalent forces that help to hold 
these complexes together. Because Grp170 is not a reductase, it cannot directly disrupt 
disulfide-bonded protein complexes such as those seen in Fig. 3-2. This suggests that 
Grp170 must operate coordinately with a bona fide ER reductase, such as PDI, to 
reduce aberrant intermolecular (and intramolecular) disulfide bonds (He et al., 2015). 
Indeed, not only are Grp170 and PDI found together in the same multiprotein complex 
(Meunier et al., 2002), but we also found that Grp170 availability promotes the 
association of PDI with Akita proinsulin. We consider it a reasonable possibility that 
Grp170-mediated disaggregation may expose disulfide bonds within the high-MW 
protein complexes, enabling PDI to more efficiently reduce these covalent bonds. Of 
note, the cytosolic counterpart of Grp170 is the Hsp110 chaperone family, including 
Hsp105 (Andreasson et al., 2010). In conjunction with a J-protein and Hsc70, Hsp105 
has been shown to trigger disaggregation of aggregated protein complexes (Mattoo et 
al., 2013; Nillegoda et al., 2015; Rampelt et al., 2012; Shorter, 2011). Additionally, the 
Hsp105-Hsc70-J-protein triad can disassemble a large viral particle in vitro (Ravindran 
et al., 2015). These findings support the possibility that Grp170 may function in concert 
87 
 
with a J-protein and BiP (the Hsp70 family member of the ER) to disaggregate high-MW 
protein complexes of misfolded proinsulin. If so, the nucleotide exchange function of 
Grp170 for BiP might serve as a pivotal link that connects the actions of these two ER 
chaperones. 
 
Restoring Insulin Secretion Concomitant with ERAD of Mutant Proinsulin 
The second critical point revealed in this study is a strategy to rectify the block in insulin 
secretion that is fundamental to the pathogenesis of MIDY. Because all such patients 
are heterozygotes, WT proinsulin is coexpressed with mutant proinsulin in MIDY (Liu et 
al., 2010a; Stoy et al., 2007). Interestingly, our analyses demonstrated that Grp170 
displays a higher affinity for Akita proinsulin compared with WT proinsulin, suggesting 
that the efficiency of association of this chaperone with proinsulin is linked to the 
misfolded state. Whereas the precise molecular feature that Grp170 recognizes within 
Akita proinsulin remains undefined, we note that when both WT and Akita proinsulin are 
coexpressed, imposing a block downstream in the ERAD pathway not only causes 
Akita-Myc to accumulate in cells, but the intracellular abundance of coexpressed WT 
proinsulin increases also (Fig. 3-5D). Moreover, coexpressed WT proinsulin associates 
much more with BiP in Akita pancreatic islets than it does in WT mouse islets (Liu et al., 
2010a). Thus, WT proinsulin that is ordinarily recognized very little by Grp170 is likely to 
display new misfolded features that are more strongly recognized by Grp170 when WT 
proinsulin enters high-MW complexes containing Akita proinsulin. 
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With this in mind, we postulate that Grp170 engagement can have simultaneous 
beneficial effects on both Akita proinsulin and coexpressed WT proinsulin. Whereas 
small oligomeric species of Akita proinsulin (enriched by Grp170) are especially 
competent for ERAD, the enrichment of small oligomeric species of WT proinsulin offer 
an opportunity to fold successfully, followed by anterograde exit of WT proinsulin from 
the ER, allowing the formation of mature bioactive insulin that becomes available for 
secretion. Indeed, we found that in cells coexpressing Akita and WT proinsulins (where 
these two proteins are locked in the high-MW protein complexes), Grp170 induction 
liberated WT proinsulin from the high-MW complexes and restored insulin (C-peptide) 
secretion that was previously limited by the presence of Akita proinsulin. The dramatic 
effects of the overexpression of Grp170 in promoting insulin secretion suggest that the 
endogenous Grp170 level may be either insufficient to prevent Akita and WT proinsulins 
from entering the high-MW complexes or insufficiently abundant to effectively 
disaggregate high-MW species of misfolded proinsulin. In an in vivo transgenic mouse 
model, overexpressing Grp170 by 1.5-fold was unable to stimulate insulin secretion 
(Ozawa et al., 2005), suggesting that this is an insufficiently high level of Grp170 to 
overcome the misfolding block of proinsulin transport that leads to insulin secretion. 
Indeed, we now recognize that Akita mouse islets already have an ER stress–induced 
increase of Grp170 that is >1.5-fold and that still greater augmentation of Grp170 
activity is required to rescue the WT proinsulin. As chemical compounds that act as 
allosteric regulators of the BiP/Hsp70 chaperones have been successfully developed (Li 
et al., 2013), it is conceivable that analogous compounds strongly stimulating Grp170 
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activity could also be generated. If so, the therapeutic benefit of such an agent in 
restoring insulin secretion should be explored. 
 
Conclusion 
This study not only identifies a new ER factor that triages a misfolded mutant proinsulin 
molecule for destruction, it also suggests a potential strategy for remedying the block in 
WT proinsulin transport that causes the insulin deficiency of MIDY. These findings may 
also have broad implications for other ER protein-misfolding diseases. 
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Figure 3-1. Grp170 knockdown impairs Akita degradation. A: 293T cells 
expressing Akita-Myc (1 µg) were transfected with scrambled or Grp170-specific siRNA. 
Cells were then treated with 100 μg/mL cycloheximide for the indicated time and 
harvested. The resulting WCE was analyzed by immunoblotting using the indicated 
antibodies. B: The Akita-Myc band intensity in A and C was quantified using ImageJ 
(National Institutes of Health). Data represent the mean ± SD of at least three 
independent experiments. C: As in A, except cells were transfected with Sil1 siRNA. 
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Figure 3-2. Depleting Grp170 increases the size of Akita oligomeric complexes. A: 
293T cells expressing Akita-Myc (1 µg) were transfected with either scrambled siRNA or 
Grp170 siRNA #2. The resulting WCE was subjected to nonreducing and reducing 
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SDS-PAGE, as indicated, and immunoblotted using the indicated antibodies. The graph 
shows quantification of the relative amount of Akita-Myc dimeric and trimeric species 
generated from at least three independent experiments. B: 293T cells expressing Akita 
were transfected with either scrambled siRNA or Grp170 siRNA #2. Cells were 
harvested, lysed, and precleared; loaded onto a 10–50% sucrose gradient; and 
ultracentrifuged for 24 h. Samples were collected into 12 fractions, subjected to 
reducing SDS-PAGE, and immunoblotted. The lower graph shows the relative quantity 
of Akita-Myc in each fraction. Data represent the mean ± SD of at least three 
independent experiments. 
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Figure 3-3. Overexpression of Grp170 stimulates Akita degradation. A: 293T cells 
expressing Akita-Myc (1 µg) and GFP-FLAG (0.25 µg) were transfected with an empty 
vector or a Grp170-FLAG plasmid (1 µg). Cells were then treated with cycloheximide for 
the indicated time and harvested, and the resulting WCE was analyzed by 
immunoblotting using the indicated antibodies. B: The Akita-Myc band intensity 
in A and C was quantified with ImageJ. Data represent the mean ± SD of at least three 
independent experiments. C: As in A, except cells were transfected with Grp170-FLAG 
(1 µg) and additional empty vector, WT p97-His, or QQ p97-His construct (0.25 μg). D: 
293T cells expressing Akita-Myc (1 µg) were transfected with GFP-FLAG or Grp170-
FLAG plasmids (1 µg). Three hours preharvest, cells were treated with 10 μmol/L 
MG132. Cells were then harvested and separated on a 10–50% sucrose gradient by 
ultracentrifugation. The resulting fractions were separated using reducing SDS-PAGE 
and subjected to immunoblotting analysis. The lower graph shows relative distribution 
of Akita-Myc in each fraction. Data represent the mean ± SD of at least three 
independent experiments. 
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Figure 3-4. Grp170 promotes the interaction of PDI with Akita proinsulin. A: 293T 
cells expressing Akita (1 µg) were transfected with GFP-FLAG or Grp170-FLAG (1 µg), 
with intoxication of SubAB (0.5 μg/mL) or mutant SubAA272B (0.5 μg/mL) where 
indicated for 6 h before harvest. FLAG-tagged proteins were immunoprecipitated from 
the resulting WCE using FLAG antibody conjugated beads. The precipitated material 
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and input were subjected to reducing SDS-PAGE as indicated and immunoblotted using 
the appropriate antibodies. The graph represents the amount of 
immunoprecipitated Akita-Myc normalized to the level of immunoprecipitated Akita-Myc 
under the SubAB (mutant) control condition. B: 293T cells expressing Akita-Myc (1 µg) 
were transfected with scrambled siRNA or PDI siRNA as indicated. Cells were 
harvested and the resulting WCEs were subjected to IP using FLAG antibody 
conjugated beads. The immunoprecipitated material and input were subjected to 
reducing SDS-PAGE as indicated and immunoblotted using the indicated antibodies. 
The graph represents the immunoprecipitated Akita-Myc level normalized to the level of 
immunoprecipitated Akita-Myc in the scrambled control. C: Similar to B, except PDI 
C56A-FLAG (1 µg) was transfected into cells transfected with scrambled siRNA or 
Grp170 siRNA #2. The resultant WCE was incubated with FLAG antibody conjugated 
beads, and the precipitated material was separated on nonreducing and reducing SDS-
PAGEs followed by immunoblotting with the indicated antibodies. Single and double 
asterisks indicate covalent adducts containing monomer or dimer of PDI C56A-FLAG 
+ Akita-Myc, respectively. The graph represents the level of PDI-Akita crosslinked 
product formation normalized to the levels of these products generated under the 
scrambled siRNA control condition. IB, immunoblot. 
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Figure 3-5. Grp170 overexpression promotes ERAD of Akita and ER export of 
coexpressed WT proinsulin. A: 293T cells expressing Grp170-FLAG (1 µg) were 
transfected with WT proinsulin-Myc or Akita-Myc (1 µg) and treated with EtOH or 2.5 
μmol/L brefeldin A for 1 h. Cells were harvested, lysed, and subjected to IP using FLAG 
antibody conjugated beads. The precipitated material and input were separated on a 
reducing SDS-PAGE and subjected to immunoblotting with the indicated antibodies. B: 
Secretion of WT proinsulin-sfGFP assay was performed in Grp170-inducible 293T cells 
under indicated transfection conditions. The extracellular medium and WCE were 
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harvested, separated on SDS-PAGE, and subjected to immunoblotting with the 
indicated antibody. C: The WT proinsulin-sfGFP band intensity in B was quantified with 
ImageJ. Data represent the mean ± SD of at least three independent experiments. The 
Student t test was used to calculate the P values. D: As in B, except cells were 
transfected with QQ p97-His (0.25 µg) where indicated. E: The MW size of WT 
proinsulin-sfGFP in the WCE in B was analyzed by sucrose sedimentation 
centrifugation, as described in Fig. 3-2B. The lower graph represents the relative level 
of WT proinsulin-sfGFP in each fraction under the indicated experimental conditions. 
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Figure 3-6. The role of Grp170 in Akita proinsulin degradation and WT proinsulin 
secretion in β-cells. A: β-Cells expressing Akita-Myc (1 µg) were transfected with 
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scrambled siRNA or Grp170 siRNA #3 (because Grp170 siRNA #1 or #2 did not 
efficiently deplete endogenous Grp170 in these cells). Cells were then treated with 
cycloheximide for the indicated time and harvested, and the resulting WCE was 
analyzed by immunoblotting using the indicated antibodies. B: The Akita-Myc band 
intensity in A was quantified using ImageJ. Data represent the mean ± SD of at least 
three independent experiments. C: β-Cells expressing Akita-Myc (1 µg) were 
transfected with GFP-FLAG or Grp170-FLAG (1 µg). Cells were then treated with 
cycloheximide for the indicated time and harvested, and the resulting WCE was 
analyzed by immunoblotting using the indicated antibodies. D: The Akita-Myc band 
intensity in C was quantified using ImageJ. Data represent the mean ± SD of at least 
three independent experiments. E: Secretion of WT proinsulin C-peptide-sfGFP assay 
was performed in the β-cells under the indicated transfection conditions. The 
extracellular medium and WCE were harvested, separated on SDS-PAGE, and 
subjected to immunoblotting with the indicated antibodies. F: The WT proinsulin C-
peptide-sfGFP band intensity in E was quantified using ImageJ. Data represent the 
mean ± SD of at least three independent experiments. The Student t test was used to 
calculate the P values. G: Endogenous Grp170 protein expression across different 
physiological and pharmacology conditions. Treatment with 2.5 μg/mL tunicamycin was 
administered for 5 h. All transient transfections consisted of 1 μg of plasmid DNA for 24 
h. Twenty-five Akita mouse islets (female) and 25 C57B/6 mouse islets (female) were 
harvested and lysed in 40 μL RIPA buffer with 10 mmol/L NEM plus protease 
inhibitors. H: A model depicting how Grp170 coordinates with PDI to promote ERAD 
of Akita (A) to restore WT proinsulin secretion (see Discussion for more details). 
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CHAPTER 4: Cells Deploy a Two-Pronged Strategy to Rectify Misfolded 
Proinsulin Aggregates 
 
INTRODUCTION 
Formation of protein aggregates is a signature of many protein misfolding diseases, 
including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and diabetes 
(Bates, 2003; Irvine et al., 2008; Mukherjee et al., 2015). Not surprisingly, there is 
intense interest in learning how to stimulate cellular mechanisms that decrease the 
levels of potentially toxic aggregates to combat disease. In principle, these mechanisms 
may be comprised of pre-emptively preventing the formation of such aggregates, as 
well as either disaggregation or clearance of the aggregated species once they have 
formed. For the development of effective therapies, it may be necessary to stimulate 
more than one mechanism to decrease aggregate accumulation.  
 
Proinsulin is the precursor of insulin, a hormone secreted by pancreatic β-cells that 
controls blood glucose levels (Steiner et al., 1967). Biosynthesis of proinsulin is initiated 
when the precursor preproinsulin translocates into the endoplasmic reticulum 
(ER)(Chan et al., 1976). Upon translocation into the ER, the signal sequence of 
preproinsulin is removed to generate proinsulin, which contains the B chain, connecting 
C-peptide, and the A-chain. Folding of proinsulin ensues with concomitant generation of 
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three conserved disulfide bonds (cysteine in the 7th residue of the B chain linked to 
cysteine in the 7th residue of the A-chain denoted as the B7-A7 disulfide bond, plus the 
B19-A20 and A6-A11 disulfide bonds). Upon proper folding, proinsulin exits the ER and 
is transported to the Golgi, and further, to immature secretorygranules. In these 
granules, bioactive insulin is formed when the C-peptide is excised, with the A and B 
chains connected via the two interchain disulfide bonds. Exocytosis of secretory 
granules ultimately releases bioactive insulin to the bloodstream. In the autosomal-
dominant diabetic syndrome called Mutant INS gene–induced Diabetes of Youth 
(MIDY), misfolded mutant proinsulin is thought to initiate disease (Liu et al., 2010b; Stoy 
et al., 2007; Weiss, 2009) with association and impaired trafficking of wild-type 
proinsulin (Cunningham et al., 2017; Hodish et al., 2010; Liu et al., 2010a; Liu et al., 
2007). Over 30 missense mutations in the human INS gene have been identified; in 
almost all cases, MIDY proinsulin mutants cannot fold properly and consequently fail to 
become bioactive insulin (Arunagiri et al., 2018). Instead, they are entrapped in the ER, 
dominantly interfering with the folding of wild type (WT) proinsulin which also becomes 
impaired in its exit from the ER, decreasing WT insulin production (Liu et al., 2010a; Liu 
et al., 2010b). However, whether misfolding of the mutant proinsulin leads to insoluble 
protein aggregation of either the mutant or WT gene product, is currently unknown. 
What is known is that decreased circulating insulin renders patients (and animal 
models) susceptible to increased blood glucose that provokes further proinsulin 
biosynthesis (both mutant and WT), exacerbating proinsulin misfolding in the ER and 
resulting in enhanced ER stress with eventual β-cell failure.   
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The best-characterized MIDY mutant is Akita proinsulin (herein simply called ‘Akita’), in 
which cysteine in the 7th position of the A chain is mutated to tyrosine, leaving cysteine 
in the 7th position of the B chain unpaired (Wang et al., 1999). This lone cysteine forms 
non-native disulfide bonds, leading to intermolecular disulfides engaging additional Akita 
molecules, which generate high molecular weight (MW) protein complexes 
(Cunningham et al., 2017; Liu et al., 2007). The accumulating presence of such 
complexes somehow recruits WT proinsulin, preventing its ER exit and secretion, which 
leads to the disease (Liu et al., 2010b). The ultimate sizes of these Akita-containing high 
MW protein complexes, and the full spectrum of ER protein quality control pathways 
available to limit the build-up of Akita-containing high MW complexes, are questions of 
direct relevance to the pathogenesis and treatment of MIDY.  
 
To date, we and others have demonstrated that one major ER quality control pathway 
called ER-associated degradation (ERAD) can dispose of soluble forms of Akita (Allen 
et al., 2004; Cunningham et al., 2017; He et al., 2015; Liu et al., 2010a). ERAD targets 
misfolded ER proteins for retrotranslocation to the cytosol for proteasomal destruction 
(Ruggiano et al., 2014; Smith et al., 2011; Tsai et al., 2002). We recently reported that 
the ER-resident chaperone Grp170, an atypical member of the Hsp70 ATPase family, 
helps to facilitate ERAD of soluble Akita which enhances the secretion of WT insulin 
(Cunningham et al., 2017). However, the mechanistic basis by which Grp170 facilitates 
ERAD could potentially involve the targeting of Akita monomers, complexes (small or 
large) or even massive insoluble species. 
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Here we demonstrate that in the ER, Akita forms detergent-insoluble protein aggregates 
that entrap WT proinsulin. Strikingly, we find that two distinct ER quality control 
pathways are coordinately deployed to help limit the levels of these aggregates. First, 
Grp170 acts to prevent the formation of detergent-insoluble Akita aggregates which 
otherwise recruit and capture WT proinsulin. Second, to the extent that detergent-
insoluble aggregates form despite Grp170 action, an ER-phagy pathway that relies 
critically upon reticulon3 (RTN3) actively removes these species. Remarkably, 
clearance of aggregated Akita restores proper intracellular transport of WT proinsulin. 
These results suggest that insoluble aggregates of Akita with WT proinsulin help to 
drive the pathogenesis of MIDY, and reveal a new potential therapeutic strategy to block 
the disease. We also report that RTN3-dependent ER-phagy disposes of two additional, 
unrelated prohormone aggregates — together, these represent the first identified 
substrates of RTN3-mediated ER-phagy, and the data highlight a more general role of 
RTN3 in the disposal of pathogenic insoluble protein complexes in the ER.   
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STAR+METHODS 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit anti-Myc Immunology 
Consultants 
Laboratory 
Cat#RMYC-
45A 
Mouse anti-Myc Laboratory of 
Kristen Verhey 
N/A 
Rabbit anti-Orp150/Grp170 Abcam Cat# 
ab124884, 
RRID:AB_10
973544 
Rabbit anti-BiP Abcam Cat# 
ab21685, 
RRID:AB_21
19834 
Mouse anti-Hsp90alpha/beta (F-8) Santa Cruz 
Biotechnology 
Cat# sc-
13119, 
RRID:AB_67
5659 
Mouse anti-PDI Abcam Cat# ab2792, 
RRID:AB_30
3304 
Mouse anti-GFP Proteintech Group Cat# 66002-
1-Ig, 
RRID:AB_11
182611 
Rabbit anti-Hrd1 Proteintech Group Cat# 13473-
1-AP, 
RRID:AB_22
87023 
Rabbit anti-Beclin1 MBL International Cat# PD017, 
RRID:AB_12
78767 
Rabbit anti-CCPG1 Proteintech Group Cat# 13861-
1-AP, 
RRID:AB_20
74010 
Rabbit anti-Sec62 [EPR9212]  Abcam Cat# 
ab137022 
Rabbit anti-RTN3 Bethyl 
Laboratories 
Cat# A302-
860A 
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Rabbit anti-RTN3 Boster Biological 
Technology 
Cat# 
PA2256, 
RRID:AB_26
65372 
Rabbit anti-FAM134B Proteintech Group Cat# 21537-
1-AP 
Rabbit anti-RTN4 Santa Cruz 
Biotechnology 
Cat# sc-
271878, 
RRID:AB_10
709573 
Rabbit anti-FLAG Millipore Sigma Cat# F7425, 
RRID:AB_43
9687 
Mouse anti-FLAG Millipore Sigma Cat# F3165, 
RRID:AB_25
9529 
Goat anti-Rabbit IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 
594 
Thermo Fisher 
Scientific 
Cat# A-
11037, 
RRID:AB_25
34095 
Goat anti-Mouse IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 
488 
Thermo Fisher 
Scientific 
Cat# A-
11029, 
RRID:AB_25
34088 
Chemicals, Peptides, and Recombinant Proteins 
Phenylmethylsulfonyl fluoride (PMSF) Acros Organics Cat# 
AC21574001
0; Cas: 329-
98-6 
N-ethylmaleimide (NEM) Millipore Sigma Cat# E3876; 
Cas: 128-53-
0 
Dithiobis-succinimidyl-propionate (DSP) 
Crosslinker 
Thermo Fisher 
Scientific 
Cat# 22585; 
Cas: 57757-
57-0 
Cycloheximide VWR Cat# 94271; 
Cas 66-81-9 
MG132 Cayman 
Chemicals 
Cat# 
10012628; 
Cas: 133407-
82-6 
DL-Dithiothreitol Millipore Sigma Cat# D0632; 
Cas: 3483-
12-3 
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BSA Millipore Sigma Cat# A6003; 
Cas: 9048-
46-8 
Grp170-FLAG (Inoue and Tsai, 
2015); This Paper 
N/A 
G41L Grp170-FLAG (Inoue and Tsai, 
2015); This Paper 
N/A 
BiP-FLAG This Paper N/A 
Ponceau-S Fisher Scientific Cat# BP103-
10; Cas: 
6226-79-5 
Bafilomycin A1 Millipore Sigma Cat# 508409 
CAS: 88899-
55-2 
Polyethylenimine Fisher Scientific Cat# 
AC17857100
0; Cas: 9002-
98-6; 7732-
18-5 
Prolong Gold Antifade Mountant with DAPI Thermo Fisher 
Scientific 
Cat# P36931 
Experimental Models: Cell Lines 
Human: HEK 293T ATCC Cat# CRL-
3216, 
RRID:CVCL_
0063 
Rat: INS1 832/13 Laboratory of 
Christopher 
Newgard 
RRID:CVCL_
7226 
Oligonucleotides 
siGrp170: GCUCAAUAAGGCCAAGUUUdTdT Millipore Sigma N/A 
siHrd1: 
GGAGACUGCCACUACAGUUGUdTdT 
Millipore Sigma N/A 
Human siBeclin1: 
GGUCUAAGACGUCCAACAAdTdT 
Millipore Sigma N/A 
Rat siBeclin1: 
GGAAGGGACAAGAGGUAAAUUdTdT 
Millipore Sigma N/A 
siCCPG1: 
UUCCAUGUACCAGCUUAGUUAdTdT 
Millipore Sigma N/A 
siSec62: 
GAAGGAUGAGAAAUCUGAAUUdTdT 
Millipore Sigma N/A 
siRTN3: 
UCAGUGUCAUCAGUGUGGUUUCUUAdTdT 
Millipore Sigma N/A 
siFAM134B: 
CAAAGATGACAGTGAATTAdTdT 
Millipore Sigma N/A 
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siRTN4: GUUCAGAAGUACAGUAAUUdTdT Millipore Sigma N/A 
Recombinant DNA 
pTarget-hProCpepMyc (Liu et al., 2010a) N/A 
pTarget-hProC(A7)Y-CpepMyc (Liu et al., 2010a) N/A 
pTarget-hProCpepSfGFP (Haataja et al., 
2013) 
N/A 
pTarget-hProC(A7)Y-CpepSfGFP (Haataja et al., 
2013) 
N/A 
pcDNA3.1-FLAG-RTN3L (Grumati et al., 
2017); Laboratory 
of Ivan Dikic 
N/A 
pcDNA3.1-FLAG-RTN3L∆6LIRs (Grumati et al., 
2017); Laboratory 
of Ivan Dikic 
N/A 
pAc-GFPC1-Sec61beta Laboratory of Tom 
Rapoport 
RRID:Addge
ne_15108 
pAc-GFPC1-Rtn3c Laboratory of Tom 
Rapoport 
N/A 
pAc-GFPC1-Rtn4a Laboratory of Tom 
Rapoport 
N/A 
pAc-GFPC1-Rtn4HD Laboratory of Tom 
Rapoport 
N/A 
pcDNA3.1-Grp170-FLAG (Inoue and Tsai, 
2015); this paper 
N/A 
pcDNA3.1-G41L Grp170-FLAG (Inoue and Tsai, 
2015); this paper 
N/A 
pcDNA3.1-FLAG-BiP This paper N/A 
pcDNA3.1-C28F POMC-FLAG (Kim et al., 2018) 
Laboratory of Ling 
Qi 
N/A 
pRc/RSV-G57S Pro-AVP-FLAG (Shi et al., 2017) 
Laboratory of Ling 
Qi 
N/A 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and 
will be fulfilled by the Lead Contacts, Peter Arvan (parvan@med.umich.edu) and Billy 
Tsai (btsai@med.umich.edu). 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS 
HEK 293T were cultured in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% fetal bovine serum in an incubator at 37°C and 5% CO2. Rat 
insulinoma INS1 832/13 cells were cultured in Roswell Park Memorial Institute medium 
(RPMI) 1640, supplemented with 10% fetal bovine serum, 10 mM HEPES (pH 7.5), 1 
mM Sodium Pyruvate, and 50 µM β-mercaptoethanol.  
 
METHOD DETAILS 
Plasmid Transfection, Cycloheximide Chase, Immunoprecipitation, and 
Immunoblotting 
Cells were seeded 1 day prior to transfection with 0.01-4 µg of plasmid DNA using 
polyethylenimine (PEI) or Lipofectamine 2000 (Invitrogen). 48 or 24 h post transfection, 
cells were harvested without treatment, treated with MG132 (10 µM) for 3 h, or treated 
with cycloheximide and chased for 0, 2, 4, and 6 h. Cells were harvested in PBS 
supplemented with 10 mM N-ethylmaleimide (NEM). For crosslinking 
immunoprecipitation experiments, cells crosslinked with DSP (per manufacturer’s 
protocol) were lysed in 500 µL of 1% Triton X-100 in HN buffer (50 mM HEPES pH 7.5, 
150 mM NaCl) containing 10 mM NEM and 1 mM PMSF. Cells were then incubated on 
ice for 10 min and centrifuged. The resulting whole cell extract was incubated with M2-
FLAG conjugated beads (Thermo Fisher) at 4°C for 2 h. Beads were washed with lysis 
buffer supplemented with NEM and PMSF, and boiled in SDS sample buffer with 100 
mM dithiothreitol (DTT). For immunoblot analysis, cells were lysed and immunoblotted 
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as previously described (Cunningham et al., 2017). Briefly, cells were lysed in 100 µL 
RIPA buffer supplemented with NEM and PMSF, incubated on ice for 10 min and 
centrifuged. The resulting extract was subjected to reducing SDS-PAGE with 100 mM 
DTT, transferred to nitrocellulose, and incubated with primary and secondary antibodies 
prior to exposure using ECL. 
 
Small interfering RNA knockdown 
Small interfering RNA (siRNA) was transfected into cells using RNAiMAX (Invitrogen), 
and cells were chased or harvested 48 h after treatment.  
 
Detergent-insolubility Assay 
Cells were lysed in 100 µL of RIPA supplemented with 10 mM NEM and 1 mM PMSF, 
and incubated on ice for 10 min and centrifuged. The extracted material represents the 
soluble fraction, while material the pellet (which was extracted by 2% SDS sample 
buffer) represents the insoluble fraction. Soluble and insoluble samples were subjected 
to SDS-PAGE and immunoblotting as described above. 
 
Sucrose Gradient Fractionation Assay 
This assay was previously described (Cunningham et al., 2017). Briefly, cells were 
lysed in RIPA buffer to generate a whole cell extract. The extract is cleared using an 
ultracentrifuge at 50,000 rpm for 20 min. The resulting cleared extract is layered on top 
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of a 10-50% or 30-70% discontinuous sucrose gradient and centrifuged on a Beckman 
SW50.1 rotor at 29,000 rpm for 24 h at 4°C. After centrifugation, 12 50 µL fractions were 
collected, and analyzed by SDS-PAGE followed by immunoblotting. 
 
Immunoprecipitation using Pooled Sucrose Fractions 
Fractions were pooled as follows: fractions 1-4, 5-8, and 9-12. 50% sucrose and HN 
buffer were added to the three pools to normalize the sucrose concentration. The 
pooled samples were incubated with anti-Myc antibody (1:200) at 4°C for 24 h, followed 
by 2 h of incubation with A/G-agarose beads (Pierce) at 4°C. The precipitated material 
was subjected to SDS-PAGE followed by immunoblotting. 
 
In vitro Aggregation Assay 
HEK 293T cells transfected with Akita-Myc were semipermeabilized in 300 µL of HCN 
buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 2 mM CaCl2), supplemented with 0.01% 
digitonin, 10 mM NEM and 1 mM PMSF. Cells were incubated on ice for 10 min, and 
centrifuged at 16,100 rpm for 10 min. This generates a supernatant fraction that 
contains cytosolic proteins, and a pellet fraction that contains membranes including the 
ER; Akita-Myc in the pellet fraction was subsequently solubilized by RIPA buffer 
containing 10 mM NEM and 1 mM PMSF. Purification of recombinant Grp170-FLAG, 
BiP-FLAG, and G41L Grp170-FLAG were prepared as previously described (Inoue et 
al., MBoC 2016). Recombinant FLAG-tagged proteins were stored at -80°C in 0.1% 
Triton X-100 in HN buffer. During the reaction, each tube contains a membrane extract 
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harboring soluble Akita-Myc, 100 µM ATP, 10 mM MgCl2, 1 mM KCl, and either 0.3 
mg/mL of BSA or the indicated purified protein (Grp170-FLAG, G41L Grp170-FLAG, or 
BiP-FLAG). Each tube was then incubated in a thermomixer (800 rpm) at 37°C for the 
indicated time: 10, 5, 3, 1, or 0 min. After incubation, the sample was centrifuged at 
16,100 g for 10 min to generate a supernatant fraction that contains soluble Akita-Myc 
and a pellet fraction that harbors aggregated Akita-Myc. Aggregated Akita-Myc was 
resuspended in a SDS sample buffer. Samples containing soluble or aggregated Akita-
Myc were subjected to reducing SDS-PAGE followed by immunoblotting. 
 
XBP1 Splicing Assay 
HEK 293T cells transfected with plasmids encoding Akita-Myc or an empty vector 
(pcDNA3.1) were co-transfected with either scrambled or RTN3 siRNA. XBP1 splicing 
assay was performed as described in (Uemura et al., 2009). 
 
Immunofluorescence Staining and Imaging 
INS1 832/13 cells were fixed with 4% PFA for 20 minutes, permeabilized with 0.2% 
Triton X-100/TBS/3% BSA for 20 minutes, and blocked with 0.2% Tween-20/TBS/3% 
BSA for one hour at room temperature. Primary antibodies were diluted in 0.2% Tween-
20/TBS/3% BSA and incubated overnight at 4°C. Secondary antibodies were also 
diluted in 0.2% Tween-20/TBS/3% BSA and incubated at room temperature for one 
hour. Cells were mounted with Prolong Gold anti-fade reagent with DAPI. Microscopy 
was performed using a Zeiss LSM 800 confocal laser scanning microscope with a Plan-
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Apochromat 40x/1.4 oil differential interference contrast (DIC) M27 objective. Images 
were processed in Zen 2.3 software. 3D reconstruction was performed on Zen 2.3 
software powered by Arivis. 
 
Proinsulin Secretion Assay 
Proinsulin secretion assay was previously described (Cunningham et al., 2017), with 
few modifications indicated below. Briefly, HEK 293T cells were transfected with a 
plasmid encoding WT proinsulin-sfGFP. 8 h post transfection, the medium was replaced 
with 500 µL of fresh medium and incubated for 16 h. Medium, the whole cell extract, 
and the insoluble samples were collected and subjected to SDS-PAGE and analyzed by 
immunoblotting. 
 
Quantification and Statistical Analysis  
 
Details on statistical analyses can be found in each figure legend. Each experiment 
shown was replicated at least n=3 times. Additionally, western blot quantification was 
performed using NIH ImageJ v1.52i with significance p<0.05.  
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RESULTS 
Depletion of Grp170 promotes formation of detergent-insoluble Akita proinsulin 
We previously used sucrose gradient sedimentation analysis to analyze the oligomeric 
state of Akita (Cunningham et al., 2017). In this experiment, HEK 293T cells transiently 
expressing Akita-Myc (in which Myc is inserted within the C-peptide domain) were lysed 
in RIPA buffer (containing 1.0% Triton X-100 and 0.1% SDS) before sedimentation on a 
10%-50% discontinuous sucrose gradient. After centrifugation, fractions were collected 
and subjected to reducing SDS-PAGE and immunoblotting using an antibody against 
Myc. As previously reported, Akita-Myc was found in all fractions (Cunningham et al., 
2017). In this report, we have defined fractions 1-4 as low MW Akita species, fractions 
5-8 as the mid MW species, and fractions 9-12 as high MW species (Fig. 4-1A). 
 
Although Grp170 was previously shown to bind to Akita and to promote its ERAD-
dependent degradation (Cunningham et al., 2017), it is unclear which size Akita 
complexes this chaperone preferentially interacts with. In a discontinuous sucrose 
gradient, the bulk of cellular Grp170 in the steady state resides in the middle of the 
gradient (Fig. 4-1B, first set of panels, “input”). Akita in the low, mid, and high MW 
species were then immunoprecipitated (with anti-Myc) and subjected to SDS-PAGE 
followed by immunoblotting with an antibody against Grp170 (Fig. 4-1B, first set of 
panels) or the ER-resident chaperone BiP (second set of panels). Strikingly, Grp170 
was specifically co-precipitated with Akita from the high MW species (Fig. 4-1B, lane 3) 
whereas pull-down of Akita from the mid MW species co-precipitated BiP (Fig. 4-1B, 
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second set of panels, lane 5). These findings demonstrate that Grp170 preferentially 
engages the high MW Akita complexes.   
 
What might be the functional significance of Grp170 binding selectively to high MW 
Akita complexes? One possibility is that this binding prevents Akita from extending even 
further to form insoluble protein complexes. To determine if Grp170 prevents higher 
order Akita aggregation, we assessed the extent to which Akita can be extracted into 
the soluble phase in RIPA buffer — the molecules resistant to extraction are referred to 
as insoluble aggregates — but can be re-solubilized under stronger detergent 
conditions (1%-2% SDS). Using this method, we found that in cells expressing Akita-
Myc and transfected with a control siRNA, Akita was extracted into the soluble fraction 
with a negligible pool of insoluble molecules (Fig. 4-1C, first panel, compare lane 1 to 
5). By contrast, upon knockdown of Grp170 [siRNA #1, (Cunningham et al., 2017)], the 
level of Akita-Myc in the insoluble fraction increased significantly (Fig. 4-1C, first panel, 
compare lane 6 to 5; quantified in right graph). Grp170 knockdown also modestly 
increased the Akita level in the soluble fraction (Fig. 4-1C, first panel, compare lane 2 to 
1). Appearance of Akita in the insoluble phase is not due to non-specific partitioning 
because neither Grp170 nor cytosolic Hsp90 appeared in this fraction under any 
condition (Fig. 4-1C, second and third panels). Hence, the observation that depleting 
Grp170 increased the level of aggregated Akita suggests that Grp170 functions to 
prevent Akita aggregation.   
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To probe the size of Akita complexes in the soluble and insoluble fraction (re-solubilized 
in SDS), we layered these fractions from Grp170-depleted cells over a heavier 30%-
70% discontinuous sucrose gradient. Whereas soluble Akita migrated to the lighter 
fractions (2-6) as expected, insoluble Akita was found only in the densest fraction (12) 
(Fig. 4-1D, compare first to second panels). However, when Akita from the insoluble 
fraction was pretreated with the reducing agent dithiothreitol (DTT), it now migrated to 
lighter fractions (2-3) (Fig. 4-1D, third panel), indicating that insoluble Akita consists of a 
massive disulfide-bonded protein complex.  
 
Given the large size of insoluble Akita, we asked to what extent proteasomal activity 
might play a role in clearing or preventing these insoluble aggregates in control cells 
(transfected only with a scrambled siRNA). However, our findings demonstrate that in 
control cells, treatment with the proteasome inhibitor MG132 increased the Akita level in 
the insoluble fraction to a lesser extent than in cells with Grp170 knockdown (Fig. 4-1C, 
first panel, compare lane 7 to 5; quantified in the right graph). Similarly, in cells 
transfected with Grp170 siRNA, the level of insoluble Akita was not enhanced by 
MG132 (Fig. 4-1C, first panel, compare lane 8 to 6; quantified in the right graph). These 
findings raise the possibility that a proteasome-independent pathway is used to remove 
aggregated Akita (see below). 
 
Grp170 prevents formation of aggregated Akita in vitro 
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Our cell-based results demonstrate that Grp170 prevents the accumulation of insoluble 
Akita aggregates. In parallel, we developed a system to directly test whether Akita-Myc 
released from an ER-containing fraction is predisposed to form aggregates in vitro.  This 
simple assay is based on the idea that Akita-Myc aggregates can be pelleted by 
centrifugation (Fig. 4-2A, top). If so, addition of Grp170 could then be tested for its 
ability to prevent Akita-Myc aggregation (Fig. 4-2A, bottom).  
 
To isolate soluble Akita-Myc, HEK 293T cells expressing Akita-Myc were first treated 
with a low digitonin concentration (0.01%) and centrifuged to generate a supernatant 
that harbors cytosolic proteins (cytosol fraction) and a pellet that contains the 
membrane fraction including the ER. When the cytosol and membrane fractions were 
subjected to SDS-PAGE, cytosolic Hsp90 was found predominantly in the cytosol 
fraction whereas the ER-resident PDI was present only in the membrane fraction 
(containing ER, Fig. 4-2B). Importantly, Akita-Myc partitioned only in the membrane 
fraction (Fig. 4-2B, third panel) and the soluble pool of proteins from this fraction were 
released with RIPA buffer. In parallel, we immunopurified FLAG-tagged WT Grp170 
(Grp170-FLAG), BiP (BiP-FLAG), and an ATPase-defective Grp170 (G41L Grp170-
FLAG) from HEK 293T cells (Fig. 4-2C).  
 
Remarkably, when soluble Akita-Myc was mixed with a control protein (bovine serum 
albumin, BSA) and incubated for various times, Akita-Myc rapidly became insoluble as 
detected by centrifugation: it was depleted from the soluble fraction within 10 min while 
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increasing in the pellet (Fig. 4-2D upper panel; Akita-Myc in the pellet is quantified in the 
right graph). In contrast, when soluble WT proinsulin-Myc was incubated with BSA and 
processed similarly, it remained mostly soluble (Fig. 4-2D. fifth panel; quantified in the 
right graph). Strikingly, when purified Grp170-FLAG (but not the ATPase-deficient G41L 
Grp170-FLAG) was added, Akita-Myc solubility was preserved (Fig. 4-2D, compare 
second to first and third panels; quantified in the right graph). Incubation of soluble 
Akita-Myc with an equal amount of BiP-FLAG also prevented insolubility of Akita, but 
was less efficient than Grp170-FLAG (Fig. 4-2D, compare fourth to second panel; 
quantified in the right graph). Together, these findings support the cell-based results 
(Fig. 4-1), demonstrating that mutant Akita proinsulin has a high propensity to 
aggregate, and that Grp170 uses an energy-driven reaction (blocked by the G41L 
mutation) to maintain Akita solubility.   
 
Grp170 prevents WT proinsulin from entering detergent-insoluble aggregates 
Because Akita is thought to dominantly interfere with the proper folding of WT proinsulin 
(Liu et al., 2007), insoluble Akita may recruit WT proinsulin entry into these insoluble 
aggregates. If so, we reasoned that Grp170’s ability to prevent formation of insoluble 
Akita aggregates might also prevent the aggregation of WT proinsulin. To test this, cells 
expressing superfolder GFP-tagged WT proinsulin (in which sfGFP is inserted in the C-
peptide domain) were transfected with scrambled or Grp170 siRNA, along with either a 
control empty vector or Akita-Myc. Indeed, expression of Akita-Myc stimulated WT 
proinsulin-sfGFP to enter into the detergent-insoluble fraction (Fig. 4-3A, first panel, 
compare lane 7 to 5; quantified in the right graph), supporting the notion that Akita 
122 
 
promotes aggregation of WT proinsulin. Knockdown of Grp170 increased the level of 
WT proinsulin-sfGFP in the detergent-insoluble fraction, and this was essentially 
additive with the insoluble WT proinsulin promoted by the presence of Akita (Fig. 4-3A, 
first panel, lanes 6-8; quantified in the right graph). Importantly, similar results were 
found when the experiments were repeated in the more physiologically-relevant rat 
pancreatic β-cell line (INS1 832/13) (Fig. 4-3B). Together, these data indicate that 
Grp170 prevents aggregation of WT proinsulin recruited by aggregated Akita. 
Intriguingly, the finding that Grp170 prevents aggregation of WT proinsulin in the 
absence of Akita suggests that Grp170 may also serve a protective role against 
misfolding of WT proinsulin.  
 
We used the aforementioned in vitro system (Fig. 4-2) to further examine this finding. 
WT proinsulin-Myc was expressed in HEK 293T cells and solubilized from an ER-
enriched fraction, using the same method noted above for Akita-Myc. When soluble WT 
proinsulin-Myc was incubated with BSA and the sample processed as before, a low 
level of WT proinsulin-Myc in the pellet fraction was detected (Fig. 4-3C, first panel; 
quantified in the bottom graph); presumably, this fraction represents the extent of 
aggregation of WT proinsulin. However, if soluble WT proinsulin-Myc was co-isolated 
from cells co-expressing sfGFP-tagged Akita (Akita-sfGFP, in which sfGFP is appended 
within the C-peptide region), incubation (with BSA) now resulted in increased insolubility 
of WT proinsulin-Myc (Fig. 4-3C, second panel; quantified in the bottom graph), 
consistent with the idea that Akita promotes the aggregation of WT proinsulin. Strikingly, 
if purified Grp170-FLAG was added, the aggregation of WT proinsulin was blocked (Fig. 
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4-3C, third panel; quantified in the bottom graph), supporting the idea that Grp170 
prevents WT proinsulin from recruitment into aggregates promoted by Akita proinsulin. 
 
Beclin1-dependent autophagy disposes of aggregated Akita  
Because additional mechanisms beyond Grp170 activity are likely to limit the 
accumulation of Akita aggregates (Fig. 4-1C), we sought to better understand the 
disposal pathways that participate in the clearance of these insoluble species. Two 
major ER quality control pathways are 1) ERAD and 2) ER-phagy, a degradative 
pathway that relies on elements of the macro-autophagy machinery in which 
subdomains of the ER are delivered to the lysosome for destruction (Bernales et al., 
2006; Bernales et al., 2007). With this in mind, we compared the extent to which the key 
ERAD component Hrd1 (Bays et al., 2001; Bordallo et al., 1998; Hampton et al., 1996) 
or a critical regulator of macro-autophagy Beclin1 (Cao and Klionsky, 2007; Kang et al., 
2011) play roles in the clearance of Akita aggregates. Remarkably, our results 
demonstrated that knockdown of Beclin1 but not Hrd1 robustly increased the level of 
Akita-Myc in the detergent-insoluble fraction (Fig. 4-4A, top panel, compare lane 8 to 6; 
quantified in the right graph).  In fact, Beclin1 knockdown caused insoluble Akita-Myc to 
increase to a level higher than that observed with Grp170 knockdown (Fig. 4-4A, top 
panel, compare lane 8 to 7; quantified in the right graph). Not surprisingly, sucrose 
sedimentation analysis (using a 30%-70% gradient) revealed that the accumulation of 
aggregated Akita-Myc after Beclin1 knockdown represents a massive protein complex, 
which is significantly larger than Akita-Myc in the soluble fraction (Fig. 4-4B). These 
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results strongly suggest that macro-autophagy is used to dispose of insoluble Akita, 
rather than ERAD (Fig. 4-1C).  
 
We next assessed the degradation rate of Akita-Myc in the insoluble and soluble 
fractions under different knockdown conditions. Whereas Akita-Myc in the insoluble 
fraction was rapidly degraded when Grp170 was depleted, its degradation was more 
stabilized in Beclin1-depleted cells (Fig. 4-4C, top panel, compare lanes 7-9 to 10-12; 
quantified in the top right graph; degradation of insoluble Akita-Myc in Hrd1-depleted 
cells was not further analyzed due to the low level of the mutant proinsulin protein at the 
initial time point). These findings, demonstrating that loss of Beclin1 significantly impairs 
the clearance of aggregated Akita, reinforce the idea that Beclin1-dependent autophagy 
is critical for degrading insoluble Akita aggregates. In contrast, degradation of Akita-Myc 
in the soluble fraction is impaired by depletion of either Hrd1, Grp170, or Beclin1 (Fig. 4-
4C, third panel, compare lanes 4-6, 7-9, and 10-12 to 1-3; quantified in the right bottom 
graph), indicating that all three gene products participate in the turnover of soluble Akita. 
By preventing Akita from aggregation, Grp170 retains mutant proinsulin in the soluble 
phase, enabling it to undergo Hrd1-mediated ERAD (He et al., 2015). However, the 
apparent role of Beclin1 in controlling the fate of soluble Akita might be indirect, i.e., 
buildup of Akita in the insoluble fraction in Beclin1-deficient cells could promote back-up 
into the soluble fraction. 
 
RTN3-dependent ER-phagy promotes degradation of Akita aggregates 
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Because Beclin1-mediated macro-autophagy is critical for removing detergent-insoluble 
Akita aggregates from the ER, we asked if specific ER-phagy receptors participate in 
this pathway. Strikingly, similar to knockdown of Beclin1, we found that depletion of 
RTN3 [but not other ER-phagy receptors including CCPG1, Sec62, or FAM134B 
(Fumagalli et al., 2016; Grumati et al., 2017; Khaminets et al., 2015; Smith et al., 2018)] 
increased the level of Akita-Myc in the detergent-insoluble fraction (Fig. 4-5A, first 
panel, compare lane 10 to 7). RTN3 exists as a long (3A) form that contains an N-
terminal extension protruding into the cytosol, and a short (3C) form lacking this 
extension; the antibody used in this experiment does not recognize RTN3C. [Although 
knockdown of CCPG1 and FAM134B moderately decreased the Akita-Myc level in the 
soluble fraction (Fig. 4-5A, first panel, compare lanes 2 and 5 to 1), this effect was likely 
due to enhanced autophagic degradation of soluble Akita that could be inhibited by the 
autophagy inhibitor bafilomycin A1 (Fig. 4-S1, top panel, compare lane 4 to 3 and lane 
10 to 9)]. Together, our analyses suggest that RTN3 exerts an important function in 
clearance of aggregated Akita from the ER. 
 
In the RTN3-depleted state, the level of Akita-Myc in the soluble fraction also 
accumulated (Fig. 4-5A, first panel, compare lane 4 to 1), supporting that a build-up of 
Akita-Myc in the insoluble fraction may lead to back-up of Akita-Myc in the soluble 
fraction. To test if this condition triggers ER stress, we examined XBP1 splicing. In 
control cells, Akita-Myc expression moderately increased XBP1 splicing (Fig. 4-5B, top 
panel, compare lane 2 to 1), consistent with a previous report (Nozaki et al., 2004), 
whereas knockdown of RTN3 induced a robust increase in ER stress response, and this 
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effect was dependent upon expression of the misfolded substrate protein, Akita-Myc 
(Fig. 4-5B, top panel, compare lanes 4 to 3). These results indicate that accumulation of 
Akita-Myc due to impairment of ER-phagy induces marked ER stress.  
 
We next evaluated if RTN4 might also facilitate degradation of aggregated Akita. In 
contrast to knockdown of RTN3, depletion of the long (4A) and short (4B) forms of 
RTN4 did not result in accumulation of Akita in the detergent-insoluble fraction (Fig. 4-
5C, first panel, compare lane 8 to 6; quantified in the bottom graph), although this did 
modestly enhance the effect of depleting RTN3 (Fig. 4-5C, first panel, compare lane 9 
to 7; quantified in the bottom graph). Thus, RTN3 appears to play a primary and specific 
role in removing Akita aggregates during ER-phagy, whereas the role of RTN4 appears 
to be secondary. This role may even be dependent on RTN3 because our binding 
analysis demonstrated that RTN3A-FLAG interacts with endogenous RTN4A and 
RTN4B (Fig. 4-5D). 
 
We then tested whether accumulation of aggregated Akita in the detergent-insoluble 
fraction that results when RTN3 is knocked down can be blocked when GFP-tagged 
RTN3C (RTN3C-GFP, which is resistant to the RTN3 siRNA) is exogenously 
expressed. Indeed, when compared to expression of the control ER membrane protein 
Sec61-GFP, expressing RTN3C-GFP robustly decreased the level of Akita aggregates 
(Fig. 4-5E. first panel, compare lanes 5 to 4). These findings verify the integrity of the 
RTN3 siRNA, unambiguously demonstrating that accumulation of aggregated Akita 
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triggered by siRNA-mediated RTN3 knockdown is not caused by unintended off-target 
effects. These data also suggest that the N-terminal cytosolic extension of RTN3 is 
dispensable in clearing aggregated Akita. Interestingly, overexpressing RTN4A-GFP 
also blocked the accumulation of aggregated Akita upon RTN3 knockdown (Fig. 4-5E, 
first panel, compare lane 6 to 4), suggesting that in the absence of RTN3, exogenously 
expressed RTN4 can replace RTN3 activity.  
 
The accumulation of aggregated Akita-Myc due to knockdown of Grp170 (instead of 
RTN3) could similarly be decreased by overexpression of RTN4HD-GFP, RTN4A-GFP, 
RTN3C-GFP, RTN3A-FLAG, or RTN3A∆LIR-FLAG (Fig. 4-5F, first panel, compare 
lanes 2-6 to 1). RTN4HD-GFP is a mutant GFP-tagged RTN4 construct lacking its N-
terminal cytosolic domain (aa 1-960) (Shibata et al., 2008), while RTN3A∆LIR-FLAG is 
a mutant FLAG-tagged RTN3A construct missing the six LC3-interacting regions (LIR) 
located in its N-terminal cytosolic domain (Grumati et al., 2017). Importantly, intact 
Beclin1 is required for any of these overexpressed proteins to efficiently decrease the 
accumulation of aggregated Akita due to knockdown of Grp170 (Fig. 4-5F, first panel, 
compare lanes 8-12 to 2-6), suggesting that macro-autophagy is essential during RTN-
dependent clearance of aggregated Akita. RTN3 also clears aggregated Akita in the 
pancreatic INS1 832/13 β-cell line because insoluble Akita-Myc in these cells is largely 
eliminated by expressing either RTN3C-GFP or RTN3A-FLAG (Fig. 4-5G, top panel, 
compare lane 5 and 6 to 4). These results demonstrate that in the physiologically-
relevant β cells, RTN3 is deployed to remove insoluble proinsulin aggregates.  
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In these β−cells, confocal image analyses revealed that siRNA-mediated knockdown of 
Beclin1 led to the formation of RTN3 puncta (Fig. 4-S2A; the percent of β−cells 
containing at least one puncta is quantified in Fig. 4-S2B). Importantly, while RTN3 does 
not appear to colocalize with Akita-Myc in control cells, these RTN3 puncta generated in 
the Beclin1-depleted cells do colocalize with Akita-Myc (Fig. 4-S2A; the percent of 
RTN3 puncta colocalizing with Akita-Myc is quantified in Fig. 4-S2C). These RTN3 
puncta, which can be further visualized by 3D-reconstruction (Fig. 4-S3), may represent 
structures that actively recruit aggregated Akita-Myc in order to initiate disposal of Akita-
Myc via the ER-phagy pathway. Our findings strongly support the idea that RTN3 acts 
as an ER-phagy receptor that couples the removal of an aggregated ER client to 
Beclin1-dependent macro-autophagy. 
 
RTN3-mediated ER-phagy clears other mutant pro-hormone aggregates 
Does RTN3-dependent removal of insoluble protein aggregates operate more 
generally? To address this, we asked if RTN3 exerts any role during protein quality 
control of other mutant prohormones, such as the C28F mutation found in the precursor 
of the pituitary hormone proopiomelanocortin (C28F POMC), and the G57S mutation 
found in the precursor of pro-arginine-vasopressin (G57S Pro-AVP). Indeed, similar to 
Akita, knockdown of RTN3 (but not FAM134B) in HEK 293T cells increased the level of 
detergent-insoluble C28F POMC-FLAG (Fig. 4-6A, first panel, compare lane 6 to 5 and 
8; quantified in graph below); this accumulation was reversed when RTN3C-GFP was 
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expressed (Fig. 4-6A, first panel, compare lane 7 to 6; quantified in graph below). A 
comparable result was observed for G57S Pro-AVP-FLAG: while depletion of RTN3 (but 
not FAM134B) enhanced the level of aggregated G57S Pro-AVP-FLAG (Fig. 4-6B, first 
panel, compare lane 6 to 5 and 8; quantified in graph below), expression of RTN3C-
GFP decreased the accumulation of aggregates (Fig. 4-6B, first panel, compare lane 7 
to 6; quantified in graph below). Thus, RTN3 functions broadly as an ER-phagy receptor 
to remove mutant prohormone aggregates. 
 
Enhanced clearance of Akita aggregates partially rescues WT proinsulin 
secretion 
Finally, we evaluated the functional consequence of RTN3-dependent clearance of pro-
hormone aggregates. In the case of Akita, our findings revealed that aggregation of 
Akita provokes aggregation of WT proinsulin (Fig. 4-3), which presumably prevents WT 
proinsulin from exiting the ER. Indeed, in HEK 293T cells transfected with WT 
proinsulin-sfGFP and an empty vector, co-expression of Akita-Myc (along with the 
control Sec61-GFP) decreased the level of WT proinsulin-sfGFP in the media (Fig. 4-
7A, first panel, compare lane 2 to 1; quantified in the bottom graph). However, 
overexpressing increasing amounts of RTN3A-FLAG partially restored WT proinsulin-
sfGFP secretion (Fig. 4-7A, first panel, compare lanes 3 and 4 to 2; quantified in the 
bottom graph). Moreover, when RTN3C-GFP, RTN4A-GFP, or RTN4HD-GFP was 
overexpressed (instead of RTN3A-FLAG) under the same experimental set-up as in 
Figure 7A, similar results were found (Fig. 4-7B-D, first panel, compare lane 4 to 2; 
quantified in the bottom graph). These findings demonstrate that clearance of Akita 
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aggregates by overexpressing RTN3 (or RTN4) can in some measure restore the WT 
proinsulin export that is needed for insulin production.   
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DISCUSSION 
 
Two ER quality control strategies work together to limit accumulation of 
misfolded proinsulin aggregates 
Formation of protein aggregates is a signature feature of many human conformational 
diseases. Hence, identifying cellular mechanisms that minimize the accumulation of 
these aggregates will likely provide therapeutic approaches to alleviate such diseases. 
In the diabetic syndrome called MIDY, misfolding of mutant proinsulin (e.g., Akita) is 
thought to initiate disease progression (Liu et al., 2010b) by entrapping WT proinsulin in 
the ER, thereby preventing production of mature insulin (Liu et al., 2010b; Liu et al., 
2007). In this manuscript, we found that in the ER, Akita forms detergent-insoluble 
aggregates that recruit WT proinsulin to also enter into these insoluble complexes (Fig. 
4-7E). Importantly, our studies reveal that cells can deploy two distinct ER-dependent 
quality control mechanisms to minimize the buildup of aggregated Akita. First, the ER-
resident Grp170 acts to prevent aggregation of Akita (Fig. 4-7E). Second, RTN3-
dependent ER-phagy removes any aggregates that are formed despite the activity of 
Grp170 (Fig. 4-7E). Enhancing the clearance of aggregated Akita restores WT 
proinsulin export, suggesting that the Akita aggregates exert an important role during 
pathogenesis of MIDY.   
 
Grp170 prevents Akita aggregation 
Using a cell-based strategy, we found that Grp170 prevents Akita from entering into a 
detergent-insoluble fraction characteristic of aggregated proteins. An in vitro 
132 
 
reconstitution approach further revealed that purified Grp170 (but not the ATPase-
defective G41L Grp170) retains Akita in the soluble fraction, suggesting that Grp170 
uses an energy-dependent chaperone activity to impede Akita aggregation. Because 
Grp170 is an established nucleotide-exchange factor (NEF) of BiP (Weitzmann et al., 
2006) and because G41L Grp170 displays attenuated NEF activity (Inoue and Tsai, 
2015), Grp170 might in principle operate in concert with BiP to prevent aggregation of 
Akita. However, this seems unlikely because depletion of BiP in cells did not lead to 
accumulation of Akita in the detergent-insoluble fraction (data not shown), and purified 
BiP did not inhibit the aggregation of soluble Akita as efficiently as Grp170. 
 
How then might Grp170 prevent Akita from aggregation? The complexes contained in 
detergent-insoluble Akita were found to be much larger than those in the soluble 
fraction, suggesting that soluble Akita progressively enlarges from the low, mid, to high 
MW species to eventually become detergent-insoluble aggregates. We also showed 
that Grp170 associates selectively with the high MW soluble species, suggesting that 
Grp170 is targeted to these species, interfering with further Akita extension into higher-
order aggregates. Indeed, a previous study reported that Grp170 (in contrast to BiP) 
preferentially interacts with aggregation-prone amino acid sequences in a client 
(Behnke et al., 2016). This raises the possibility that when Akita multimerizes into the 
high MW species, it adopts a physical conformation in which aggregation surfaces are 
preferentially displayed, thereby recruiting Grp170. The idea that Grp170 prevents 
aggregation of Akita is also in agreement with previous studies suggesting that this 
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chaperone can block aggregation of the model substrate luciferase under an artificial 
heat treatment condition (Park et al., 2003). 
 
We previously reported that Grp170 uses its chaperone activity to facilitate ERAD-
dependent degradation of soluble Akita (Cunningham et al., 2017). We believe that by 
shifting the substrate from higher to lower MW species, Akita becomes more competent 
to undergo ERAD. Based on our new results, we hypothesize that the high MW species 
of Akita is a dynamic protein complex that continually experiences extension and 
shrinking – by blocking the extension of high MW Akita, Grp170 in turn favors the 
generation of the low MW species, which can be disposed of by ERAD to the extent that 
its accumulation does not exceed the capacity of the ERAD pathway. 
 
In MIDY, pancreatic β-cells harbor one WT and one mutant copy of the INS gene. In this 
setting, we found that aggregated Akita proinsulin recruits the aggregation of WT 
proinsulin. These findings were observed in HEK 293T cells and a pancreatic β-cell line, 
highlighting their physiological significance. Because aggregated WT proinsulin cannot 
exit the ER required for its subsequent processing, the formation of combined mutant-
WT aggregates represents a critical reaction that impairs insulin production, which is 
central to the pathogenesis of MIDY. Whether other MIDY mutations also cause their 
encoded protein products to form insoluble aggregates is presently unknown. 
Importantly, Grp170 suppresses aggregation of WT proinsulin recruited by Akita. This 
may reflect the ability of Grp170 to block aggregation of Akita, which in turn prevents 
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WT proinsulin from aggregating. However, our cell-based studies also found that 
Grp170 suppresses aggregation of WT proinsulin even in the absence of Akita, 
suggesting that WT proinsulin itself might have some predisposition to misfold and 
aggregate independent of any dominant interfering effect of mutant proinsulin. In such a 
circumstance, WT proinsulin would directly benefit from the action of Grp170. Thus, 
prevention of WT proinsulin aggregation in MIDY is likely through the activity of Grp170 
on both mutant and WT proinsulin. 
 
RTN3-dependent ER-phagy pathway clears Akita aggregates 
In addition to the action of Grp170, we postulate that cells deploy additional 
mechanisms to minimize the accumulation of aggregated prohormones. This would 
provide cells with a clear advantage in maintaining proper proteostasis, as dysfunction 
in any one pathway can be compensated by the other. Indeed, our results identify 
RTN3-dependent ER-phagy as an ER protein quality control pathway that removes 
aggregated Akita. The best evidence in support of this idea is that depletion of RTN3 
results in accumulation of detergent-insoluble Akita, indicating that RTN3 promotes 
clearance of Akita aggregates. Additionally, under this depleted condition, expression of 
the short isoform of RTN3 (called RTN3C) is sufficient to eliminate insoluble Akita 
proinsulin. Because this short isoform lacks the N-terminal cytosolic domain that 
harbors LC3-interacting regions (LIR) typically used to recruit core autophagy 
components, this result raises intriguing questions about how RTN3 is functionally 
linked to the macro-autophagy pathway during clearance of aggregated Akita. We 
envision two possibilities. First, RTN3C may oligomerize with other ER membrane 
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proteins that harbor LIRs and in this way, RTN3C is indirectly connected to the 
autophagy pathway. For instance, because RTN3 oligomerizes with RTN4, which plays 
a secondary role in clearance of aggregated Akita and has primary amino acid 
sequences in its cytosolic domain that resemble LIRs, RTN3C may partner with RTN4 
to eliminate aggregated Akita via autophagy. Second, RTN3 might use an LIR-
independent but Beclin1-dependent macro-autophagy pathway to remove aggregated 
Akita. Distinguishing these two possibilities clearly will require further investigation.  
 
In this context, we note a previous report demonstrating that full-length RTN3, via its 
LIR domains, functions as an ER-phagy receptor in the turnover of tubular ER during 
starvation (Grumati et al., 2017). Whether RTN3 in this process operates in the same 
manner as during the removal of specific ER aggregated client proteins remains 
unclear. By image analyses, we found that RTN3 forms puncta when the macro-
autophagy machinery is disabled; importantly, under this condition, the RTN3 puncta 
colocalize with Akita. One possible interpretation of this finding is that aggregated Akita 
is actively recruited into RTN3-containing puncta from which disposal of Akita is initiated 
via the ER-phagy pathway.  
 
Regardless of the precise mechanism, reticulon-driven clearance of Akita aggregates 
results in improved ER export of WT proinsulin. Because Akita aggregates recruit WT 
proinsulin, removal of aggregated Akita would enable WT proinsulin to remain in the 
soluble phase so that it can proceed via anterograde intracellular transport, an essential 
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step in the production of mature insulin. These observations suggest that enhancing the 
activity of RTN3-mediated autophagy might offer a new therapeutic strategy to 
ameliorate MIDY. Moreover, given that a low level of WT proinsulin itself also 
aggregates, this strategy might have therapeutic value to combat the pathogenesis of 
other forms of diabetes.  
 
Beyond mutant proinsulin, our findings that RTN3 eliminates misfolded POMC and pro-
AVP aggregates suggest that this ER-phagy receptor serves other protein clients and 
may function in a general mechanism to dispose of prohomone aggregates. Elucidating 
the structural features that enable these prohormone aggregates to exploit the function 
of RTN3 requires future investigations. Regardless, these data raise the possibility that 
therapeutic approaches targeting this ER-phagy receptor might have broader 
implications for a number of distinct human conformational diseases.  
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Figure 4-1. Depletion of Grp170 promotes formation of detergent-insoluble Akita. 
A. A whole cell extract derived from HEK 293T cells transfected with Akita-Myc was 
layered over a discontinuous 10-50% sucrose gradient. The sample was centrifuged, 
and each fraction (fractions 1-12) was subjected to SDS-PAGE followed by 
immunoblotting with an Myc antibody to detect Akita-Myc. Akita-Myc in fractions 1-4 is 
referred to as the low MW species, fractions 5-8 as the mid MW species, and fractions 
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9-12 as the high MW species. B. Fractions 1-4, 5-8, and 9-12 were pooled, and Akita-
Myc from the pooled fractions were immunoprecipitated. The precipitated material was 
subjected to SDS-PAGE followed by immunoblotting with the indicated antibodies. C. 
Cells expressing Akita-Myc and transfected with either a scrambled (control) or Grp170 
siRNA were treated with or without MG132, and lysed with a RIPA buffer. After 
centrifugation, the supernatant represents the soluble fraction and the pellet represents 
the insoluble fraction; material the insoluble fraction was resuspended in a sample 
buffer containing 2% SDS. Both the soluble and insoluble fractions were subjected to 
SDS-PAGE followed by immunoblotting with the indicated antibodies. The protein levels 
revealed by Ponceau staining of the insoluble fraction serve as the loading control. The 
intensity of the Akita-Myc band was quantified with ImageJ (NIH). The right graph 
depicts the insoluble Akita-Myc level normalized to the level of insoluble Akita-Myc 
present in the scrambled control. Data represent the mean ± SD of at least three 
independent experiments; p-values are generated from student’s T-test. The black line 
indicates that an intervening lane from the same blot has been excised. D. The soluble 
(first panel) and insoluble (second panel) fractions derived from Grp170-depleted cells 
expressing Akita-Myc were layered over a 30-70% discontinuous sucrose gradient and 
centrifuged as in A. Each fraction was collected, subjected to SDS-PAGE, and 
immunoblotted with an antibody against Myc. The insoluble fraction was also treated 
with DTT prior to sucrose gradient analysis (third panel). 
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Figure 4-2. Grp170 prevents formation of aggregated Akita in vitro. A. Schematic of 
the in vitro aggregation assay. (top) When Akita-Myc present in a membrane extract 
aggregates, it forms a pellet after centrifugation. (bottom) However, if the membrane 
extract containing Akita-Myc was incubated with purified Grp170, aggregation is 
prevented. Thus Akita-Myc remains in the soluble phase even after centrifugation. B. To 
generate Akita-Myc in the membrane extract, HEK 293T cells expressing Akita-Myc 
were treated with digitonin and centrifuged to generate two fractions. The supernatant 
fraction contains cytosol proteins (cytosol) and the pellet fraction harbors membranes 
including the ER (membrane); as Akita-Myc resides in the ER, it is expected to be in the 
membrane fraction. Both the cytosol and membrane extracts were subjected to SDS-
PAGE followed by immunoblotting with the indicated antibodies. C. Coomassie gel of 
purified FLAG-tagged Grp170 (lane 1), BiP (lane 2), G41L Grp170 (lane 3), as well as 
the control protein BSA (lane 4). D. (1st – 4th panels) A membrane fraction containing 
Akita-Myc was incubated with the indicated purified protein for the indicated time. The 
samples were centrifuged, and the supernatant material separated from the pellet; the 
pellet material was resuspended in a sample buffer containing 2% SDS. Both the 
supernatant and pellet material were analyzed by SDS-PAGE followed by 
immunoblotting with an antibody against Myc. (5th panel) A membrane extract 
containing WT proinsulin-Myc was incubated with BSA, and processed as above. The 
right graph represents the percentage of Akita (or WT proinsulin)-Myc in the pellet 
fraction compared to the total Akita-Myc signal at each time point from both the soluble 
and pellet fractions. Data represented the mean ± SD of at least three independent 
experiments. The black line indicates that an intervening lane from the same blot has 
been excised. 
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Figure 4-3. Grp170 prevents WT proinsulin from entering detergent-insoluble 
aggregates. A. HEK 293T cells expressing WT proinsulin-sfGFP were transfected with 
scrambled or Grp170 siRNA along with either Akita-Myc, or an empty vector. Cells were 
processed to generate the soluble and insoluble fractions as in 4-1C. The right graph 
depicts the insoluble WT proinsulin-sfGFP level normalized to the level of insoluble WT 
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proinsulin-sfGFP present in the scrambled/empty vector control. Data represent the 
mean ± SD of at least three independent experiments; p-values are generated from 
student’s T-test. B. As in A, except data were generated from rat INS1 832/13 cells. The 
black line indicates that an intervening lane from the same blot has been excised. C. In 
vitro aggregation of WT proinsulin-Myc. A membrane extract derived from cells 
transfected with either WT proinsulin-Myc and an empty vector, or WT proinsulin-Myc 
and Akita-sfGFP were incubated with either BSA or Grp170-FLAG. Samples were 
processed as in 4-2D. The bottom graph represents the percentage of WT proinsulin-
Myc in the pellet fraction as compared to the total WT proinsulin-Myc signal at each time 
point from both the soluble and pellet fractions. Data represents ± SD of at least three 
independent experiments. The black line indicates that an intervening lane from the 
same blot has been excised. 
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Figure 4-4. Beclin1-dependent autophagy disposes aggregated Akita. A. HEK 
293T cells were transfected with Akita-Myc and either scrambled, Hrd1, Grp170, or 
Beclin1 siRNA. Soluble and insoluble fractions were generated and processed as in 4-
1C. The right graph represents insoluble Akita-Myc level normalized to the level of 
insoluble Akita-Myc in the scrambled control. Data represent the mean ± SD of at least 
three independent experiments; p-values from student’s T-test. B. As in 4-1D, except 
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the soluble (first panel) and insoluble (second panel) fractions were derived from 
Beclin1-depleted cells. C. HEK 293T cells expressing Akita-Myc and transfected with 
indicated siRNAs were treated with cycloheximide for 0, 2, 4 h. Soluble and insoluble 
fractions were generated as in 4-1C. Samples were subjected to SDS-PAGE and 
immunoblotted with the indicated antibodies. The top right graph represents the 
percentage of insoluble Akita-Myc remaining, and the bottom right graph represents the 
percentage of soluble Akita-Myc remaining. Data represents mean ±SD of at least three 
independent experiments. 
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Figure 4-5. RTN3-dependent ER-phagy promotes degradation of Akita aggregates. 
A. siRNA screen of known ER-phagy receptors. HEK 293T cells expressing Akita-Myc 
were transfected with the indicated siRNAs. Soluble and insoluble fractions were 
generated and processed as in 4-1C. B. HEK 293T cells transfected with an empty 
vector or an Akita-Myc plasmid were co-transfected with either scrambled or RTN3 
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siRNA. RNA was extracted, reverse transcribed to cDNA, and the cDNA amplified using 
PCR. C. Cells transfected with the indicated siRNA(s) were processed as in A. The 
bottom graph represents insoluble Akita-Myc level normalized to the level of insoluble 
Akita-Myc in the scrambled control. Data represent the mean ± SD of at least three 
independent experiments; p-values from student’s T-test. The schematic depicts the 
topology of RTN3A, RTN3C, RTN4A, RTN4B. RTN3A contains 6 LIR domains not 
present in RTN3C. The black line indicates that an intervening lane from the same blot 
has been excised. D. HEK 293T cells transfected with the indicated construct were 
chemically crosslinked with DSP. The resulting cell extract was subjected to FLAG-
immunoprecipitation, with the immunoprecipitated material analyzed by SDS-PAGE and 
immunoblotting. E. RTN3-depleted cells expressing Akita-Myc were transfected with 
Sec61-GFP, RTN3C-GFP, or RTN4A-GFP. Soluble and insoluble fractions were 
generated and processed as in 4-1C. The bottom graph represents the percentage of 
insoluble Akita-Myc normalized to the level of the Sec61-GFP condition. Data represent 
the mean ± SD of at least three independent experiments; p-values from student’s T-
test. F. Cells expressing Akita-Myc that were depleted of either Grp170 alone or Grp170 
and Beclin1 were transfected with the indicated constructs. The soluble and insoluble 
fractions were generated and processed as in 4-1C. G. The rat pancreatic β cell line 
(INS1 832/13) was transfected with the indicated constructs. The soluble and insoluble 
fractions were generated and processed as in 4-1C. 
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Figure 4-6. RTN3-mediated ER-phagy clears mutant prohormone aggregates. A. 
HEK 293T cells expressing C28F POMC-FLAG were co-transfected with scrambled, 
RTN3, or FAM134B siRNA, along with either Sec61-GFP or RTN3C-GFP. Soluble and 
insoluble fractions were generated as in 4-1C. The bottom graph represents insoluble 
C28F POMC-FLAG level normalized to the level of insoluble C28F POMC-FLAG in the 
scrambled control + Sec61-GFP. Data represent the mean ± SD of at least three 
independent experiments; p-values generated from student’s T-test. B. as in A, except 
cells were transfected with G57S Pro-AVP-FLAG. The bottom graph represents 
insoluble G57S Pro-AVP-FLAG level normalized to the level of insoluble G57S Pro-
AVP-FLAG in the scrambled control + Sec61-GFP. 
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Figure 4-7. Enhanced clearance of Akita aggregates partially rescues WT 
proinsulin secretion. A. HEK 293T cells expressing WT proinsulin-sfGFP were 
transfected with the indicated construct. Media and cells were harvested. Cells were 
lysed and the samples subjected to SDS-PAGE followed by immunoblotting with the 
indicated antibodies. The bottom graph represents WT proinsulin-sfGFP level in the 
media normalized to the empty vector/Sec61-GFP condition (lane 1). Data represent the 
mean ± SD of at least three independent experiments; p-values from student’s T-test. B. 
As in A, except RTN3C-GFP was used. C. As in A, except RTN4A-GFP was used. D. 
As in A, except RTN4HD-GFP was used. E. Model depicting the coordinated 
deployment of a two-pronged approach to minimize the level of Akita aggregates. The 
MIDY disease results when a mutant proinsulin molecule such as Akita misfolds, 
forming detergent-insoluble aggregates. These aggregates sequester WT proinsulin in 
the ER, thereby preventing its proper exit from the ER, maturation and secretion, 
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leading to disease. To rectify this, Grp170 actively prevents formation aggregated Akita. 
If aggregated Akita forms despite the activity of Grp170, RTN3-mediated ER-phagy is 
able to efficiently remove the aggregates through a Beclin1-dependent macro-
autophagy mechanism.  
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Figure 4-S1. Bafilomycin A1 treatment restores the decrease in soluble Akita-Myc 
level in CCPG1- or FAM134B-depleted cells. As in Figure 4-5A, except cells were 
treated with 100 nM of bafilomycin A1 (Baf A1) for 12 h. 
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Figure 4-S2. RTN3 puncta form in Beclin1-depleted β-cells which colocalize with 
Akita-Myc. A. INS1 832/13 cells transfected with the indicated siRNAs for 48 h 
and Akita-Myc for 24 h were fixed, permeabilized, and stained for the indicated 
antibodies. Images were taken on a Zeiss LSM 800 confocal microscope.  Scale bars 
are 20 µm. B. Quantification of the percentage of cells in A containing at least one 
RTN3 puncta. The number within the parenthesis indicates the number of cells 
analyzed in each condition. C. Quantification of the percentage of RTN3 puncta in 
Beclin1-depleted cells in A colocalizing with Akita-Myc. The number within the 
parenthesis indicates the number of cells analyzed. Colocalization was determined by 
analyzing all Z-stacks taken of each cell. 
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Figure 4-S3. 3D reconstruction of RTN3 puncta in Beclin1-depleted β-cell which 
colocalize with Akita-Myc. 3D reconstruction of Beclin1-depleted cell in Fig. 4-S2A 
using the Zen software powered by Arivis. Red arrows on the x,y,z axes indicate the 
angle of observation. 
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CHAPTER 5: Conclusion 
This thesis elucidates how cells deploy concerted ER protein quality control pathways to 
dispose Akita mutant proinsulin. In Chapter 2, we identified cellular components that 
target Akita mutant proinsulin along the ERAD pathway for degradation. Specifically, we 
find that the ER luminal oxidoreductase PDI reduces Akita high MW complexes, 
generating smaller oligomeric species that are competent to undergo ERAD through the 
Hrd1-Sel1L-p97 axis. In Chapter 3, we begin to clarify a role for Grp170, an atypical ER-
resident Hsp70, in ERAD-dependent clearance of Akita. A major finding in this chapter 
is that Grp170 overexpression stimulates Akita degradation which enables efficient WT 
insulin secretion – this provides a rational therapeutic strategy to alleviate the MIDY 
disease. In Chapter 4, our mechanistic studies reveal that Grp170 acts to prevent 
formation of Akita insoluble aggregates, while the ER membrane protein RTN3 disposes 
these aggregates via ER-phagy. Importantly, RTN3-mediated ER-phagy also degrades 
other prohormone aggregates. These data uncover the first series of substrates 
degraded by RTN3-dependent ER-phagy.  
 
ERAD is responsible for degrading a variety of misfolded ER substrates, including the 
Akita mutant proinsulin. In the ER lumen, Akita first encounters PDI and Grp170. PDI is 
the canonical member of the PDI family. Each of the twenty family members, excluding 
ERp29, contains a Cys-X-X-Cys motif (where X is any amino acid) that is responsible 
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for isomerization, reduction, and oxidation reactions (Benham, 2012; Ellgaard and 
Ruddock, 2005). An outstanding question is how each of these enzymes display 
selectivity for their substrates. For instance, in the case of Akita, PDI (but not p5 or 
ERdj5) binds to and catalytically reduces the disulfide bonds present in Akita high MW 
oligomers, producing smaller Akita species competent to undergo ERAD (Chapter 2, 
Figure 2-4). Whether PDI can reduce disulfide bonds of other MIDY mutant proinsulins 
is unknown, and requires additional experimentations. Although PDIa5 can bind to Akita 
(Gorasia et al., 2016 BBA), there is no evidence that it reduces the disulfide bonds of 
Akita high MW oligomers. Thus, structural features enabling a functional interaction 
between PDI and Akita remain unclear to date. It is interesting to note that while PDI is 
also required for proAVP degradation through ERAD (Shi et al., 2017), the role of other 
PDI family members in this pathway remains unknown. 
 
In Chapter 3, our analysis identified Grp170, an atypical Hsp70, as a luminal chaperone 
that acts in concert with PDI to facilitate Akita degradation via the ERAD pathway. 
Mechanistically, Grp170 either promoted the disaggregation of high MW Akita 
aggregates, or prevented the formation of these aggregates. This question was 
resolved in Chapter 4, in which we used cell-based and a partially purified reconstituted 
system to unambiguously demonstrate that Grp170 functions to prevent formation of 
high MW Akita aggregates. This is consistent with a seminal study showing that Grp170 
uniquely recognizes amino acid sequences that are prone to aggregation (Behnke et al., 
2016). The idea that Grp170 can prevent protein aggregate formation is not without 
precedent, as this chaperone had been shown to prevent heat-induced aggregation of 
158 
 
the luciferase artificial substrate (Park et al., 2003). Our findings establish Akita as the 
first endogenous substrate that is prevented from aggregation by Grp170. Beyond 
MIDY, Grp170 has also been shown to maintain cellular homeostasis in models of type 
2 diabetes (Ozawa et al., 2005); whether Grp170’s ability to prevent protein aggregation 
is responsible for this phenotype is unclear and deserves further attention. Because 
Grp170 expression is high in purkinje neurons whose destruction due to protein 
aggregation can lead to neurodegenerative diseases (Kitao et al., 2004), Grp170 may 
serve a protective role in this context. 
 
Although our data demonstrated Grp170’s ability to prevent protein aggregation, 
whether it can drive disaggregation of preformed protein aggregates remains an open 
question. Grp170 is homologous to cytosolic Hsp110, which is responsible for various 
chaperone-mediated client triage reactions in the cytosol. Interestingly, Hsp110 is also a 
key component of a recently discovered cytosolic disaggregation complex (Nillegoda et 
al., 2015). In this complex, Hsp110, along with Hsp70 and Hsp40 J proteins, functions 
to disaggregate different model clients such as luciferase and α-synuclein fibrils in vitro. 
Thus, if a homologous ER-resident disaggregation machinery exists, Grp170 is likely a 
component of this complex. Other members of this putative disaggregation machinery 
are likely BiP (homologous to Hsp70), and ERdj3 and ERdj4 (ER-resident J proteins). 
 
The coordinated action of PDI and Grp170 on Akita ultimately generates a soluble, low 
MW species poised to undergo retrotranslocation across the ER membrane to reach the 
cytosol. In Chapter 2, we demonstrated that the soluble Akita species are degraded via 
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the canonical ER membrane-bound E3 ubiquitin ligase Hrd1. Another transmembrane 
E3 ubiquitin ligase that executes a critical role in ERAD is called GP78. Although the 
role of this E3 ubiquitin ligase in facilitating Akita degradation remains to be tested, 
neuroserpin polymers that accumulate in the ER were shown to be degraded in a 
GP78-dependent mechanism (Ying et al., 2011).  
 
One of the major unanswered questions in ERAD is how the actual process of 
retrotranslocation – in which a misfolded ER substrate crosses a proteinaceous channel 
embedded in the ER membrane to reach the cytosol – is accomplished. Strong 
biochemical evidence depicts a model in which Hrd1 serves as the protein-conducting 
channel (Baldridge and Rapoport, 2016; Schoebel et al., 2017). In this model, the 
transmembrane helices 3-8 (TM3-8) of Hrd1 form a pore through which misfolded 
substrates can be funneled (Schoebel et al., 2017). By cryo-EM structural analysis, this 
pore is envisioned to be regulated by the TM1 helix of a partner Hrd1 molecule, forming 
a functional dimer. Although GP78, RNF145 and RNF139 (two additional membrane-
bound E3 ligases implicated in ERAD) have sequence similarities to Hrd1, it is unclear 
whether any of these proteins form pores comparable to Hrd1. Further, how any of the 
E3 ubiquitin ligases select specific misfolded substrates to guide them across the ER 
membrane and into the cytosol remains equally enigmatic.  
 
Acting in parallel to ERAD, we found that ER-phagy also disposes Akita. Specifically, 
the aggregated form of Akita is degraded by a RTN3-mediated ER-phagy pathway 
(Chapter 4, Figure 4-5-7). This pathway is also responsible for degradation of two 
160 
 
additional prohormone aggregates. Collectively, these results identified a first series of 
substrates for RTN3-mediated ER-phagy. ER-phagy is a relatively new field of research, 
with the initial identification of Atg39 and Atg40 in yeast and FAM134B in mammalian 
cells as ER-phagy receptors (Khaminets et al., 2015; Mochida et al., 2015). After these 
discoveries, Sec62, RTN3, and CCPG1 were shown to be additional ER-phagy 
receptors (Fumagalli et al., 2016; Grumati et al., 2017; Smith et al., 2018). Indeed, many 
new questions have emerged based on these findings.  
 
A key question is the identity of the endogenous substrates for ER-phagy, as well as 
how the substrates are recognized by the individual ER-phagy receptors. Prior to our 
work, several ER-phagy substrates were identified, including procollagen, mutant 
NPC1, and alpha-1-antitrypsin Z variant polymers for the FAM134 receptor (Forrester et 
al., 2019; Fregno et al., 2018; Schultz et al., 2018), and trypsinogen, amylase, and 
CBPA for the CCPG1 receptor (Smith et al., 2018). Our results identified Akita, C28F 
POMC, and G57S Pro-AVP aggregates as substrates for RTN3-mediated ER-phagy. 
Because the RTN3-mediated substrates identified in this thesis are all prohormone 
aggregates, these findings raise the possibility that mutant prohormone aggregates may 
generally exploit RTN3 as their ER-phagy receptor.  
 
RTN3 and FAM134B are ER membrane proteins that do not fully traverse both leaflets 
of the ER lipid bilayer but instead only insert into the cytosolic leaflet of this membrane 
(Fregno and Molinari, 2018). As a result, they do not extend into the ER lumen. This is 
in contrast to RTN4/NOGO, which is thought to traverse the entire ER membrane 
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(Schwab, 2010). The topology of RTN3 and FAM134B raises an interesting conundrum: 
if these receptors are not exposed to the ER lumen, how do they capture the luminally-
localized aggregates? One resolution to this problem can be seen in the case of the 
substrate procollagen. Procollagen is an ER luminal substrate of FAM134B-mediated 
ER-phagy. Strikingly, procollagen binds to calnexin, an ER transmembrane protein with 
a large luminal domain that typically engages misfolded soluble glycoproteins (Williams, 
2006); importantly, calnexin itself associates with FAM134B (Fregno et al., 2018). Thus 
calnexin acts as the direct cargo-binding receptor, linking procollagen to FAM134B for 
ER-phagy. It is worth noting that FAM134B is localized to ER sheets (a subdomain 
within the complex ER network), while RTN3 is found in the ER-tubule rich subdomain 
of the ER. 
 
What mechanism might enable RTN3 to engage the aggregated substrate? Reticulons 
are ER membrane morphogenic proteins that induce membrane curvature to ER 
tubules. These tubules are approximately 60-100 nanometers in diameter (Voeltz et al., 
2002), which limits the physical space needed to accommodate the large ER luminal 
aggregates. We envision two distinct mechanisms by which RTN3 captures its luminal 
substrate. In one mechanism, RTN3 complexes with a transmembrane protein 
containing a luminal domain, which in turn directly binds to the substrate; this would be 
reminiscent of the mechanism by which FAM134B interacts with its substrate. Perhaps 
an unbiased biochemical IP-mass spectrometry approach to identify RTN3 membrane-
binding partners is a reasonable strategy to test this mechanism. 
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In a second mechanism, we envision that a large aggregate might mechanically induce 
stress to the inner leaflet of the ER due to its large size. The tension exerted on the 
membrane recruits RTN3 to this site, resulting in ER-phagy of the surrounding ER 
tubule and as a consequence, removal of any luminal constituents in this ER 
subdomain. To test this second mechanism, an inducible oligomerization system (i.e. 
chemically-induced dimerization strategy such as the FRB-FKBP system) could be used 
to artificially generate an aggregated model substrate in the ER lumen via 
oligomerization of the substrate (DeRose et al., 2013). As this artificial aggregated 
substrate is unlikely to have a cognate receptor in the ER, its ability to use RTN3-
mediated ER-phagy would suggest a mechanical stress-induced mechanism operates 
to “activate” the RTN3 pathway. 
 
In principle, CCPG1 and potentially Sec62 do not require an additional cargo receptor to 
recruit a luminal substrate because these two ER-phagy receptors contain ER luminal 
domains. CCPG1 has a 518 amino acid luminal tail, which could directly engage the 
aggregated substrate. Sec62 has a small luminal domain containing only 16 amino 
acids between two transmembrane domains, so its requirement for substrate 
identification and engagement could be limited without a cargo receptor.  
 
In conclusion, my thesis revealed that cells deploy coordinated ER protein quality 
control mechanisms to dispose the MIDY mutant proinsulin Akita. We believe these 
insights should lay the foundation for many future studies that will illuminate various 
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aspects of ER protein quality control, protein misfolding dynamics, and homeostatic 
mechanisms underlying the MIDY disease.  
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